


JONES DAY

NORTH POINT • 901 LAKESIDE AVENUE • CLEVELAND, OHIO 44114-115
TELEPHONE: 216-586-3939 • FACSIMILE: 216-579-0212



06018712

Direct Number: (216) 586-7314
kjcorrigan@jonesday.com


JP412523:1418885
930210-005011

November 20, 2006

File No. 82-3349

VIA HAND DELIVERY

Securities and Exchange Commission
Office of International Corporate Finance
100 F Street NE
Washington, DC 20549



SUPPL

Re: Bespak plc -- Submission Pursuant to Rule 12g3-2(b) under the Securities and Exchange Act of 1934 -- SEC File No. 82-3349

Ladies and Gentlemen:

We are submitting the following information to the Securities and Exchange Commission (the "Commission") on behalf of Bespak plc (the "Company"), a corporation organized under the laws of England, in order for it to continue to claim exemption from the registration requirements of Section 12(g) of the Securities Exchange Act of 1934 (the "Exchange Act") available to foreign private issuers pursuant to Rule 12g3-2(b) under the Exchange Act.

Attached hereto are documents furnished pursuant to Rule 12g3-2(b)(1)(i) under the Exchange Act, of the information that, since its prior submission, the Company has:

1. made public pursuant to the laws of England;
2. filed with the London Stock Exchange and which was made public by such exchange; or
3. distributed to its security holders.

PROCESSED

NOV 20 2006

THOMSON
FINANCIAL

Pursuant to Rule 12g3-2(b)(4) under the Exchange Act, we are enclosing one copy of each of the documents.

Please note that a list identifying information of the type referenced above and stating when and by whom it is required to be made public pursuant to the laws of England, filed with any exchange or distributed to security holders was attached as Schedule II to the Company's initial submission to the Commission dated July 16, 1992.

DeWitt/22

CL1-1469335v1

Securities and Exchange Commission
November 20, 2006
Page 2

We believe that this letter and the enclosed documents satisfy the ongoing reporting requirements indicated in subparagraph (b)(1)(iii) of Rule 12g3-2 under the Exchange Act and we respectfully request that this submission be duly recorded. If you have any questions or require any additional information, please contact me at 216-586-7314.

Please acknowledge receipt of this letter and the enclosures by stamping the enclosed copy of this letter and returning it to our messenger.

Sincerely,

A handwritten signature in black ink, appearing to read "Karen J. Corrigan", with a long horizontal flourish extending to the right.

Karen J. Corrigan

cc: Ms. Jenny Owen (Bespak plc) (w/o enc.)
Ms. Elizabeth Robertson (Jones Day - London) (w/o enc.)
Mr. Louis Rorimer (Jones Day - Cleveland) (w/o encl)



a Financial Express and Inclave Media partnership

Bepak PLC - Holding(s) in Company

Bepak PLC
22 May 2006

NOTIFICATION OF MAJOR INTERESTS IN SHARES

1. Name of company

Bepak plc

2. Name of shareholder having a major interest

Aviva plc and its subsidiaries

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18

As in 2 above

4. Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them

Morley Fund Management Ltd:

BNY Norwich Union Nominees Limited	209,966*
Chase GA Group Nominees Limited	612,950*
Chase Nominees Limited	29,173*
CUIM Nominee Limited	187,211*
Vidacos Nominees Limited	14,816*

* denotes beneficial interest

5. Number of shares / amount of stock acquired

n/a

6. Percentage of issued class

n/a

7. Number of shares / amount of stock disposed

252,629

8. Percentage of issued class

0.90%

9. Class of security

Ordinary GBP0.10 shares

10. Date of transaction

17 May 2006

11. Date company informed

22 May 2006

12. Total holding following this notification

1,054,116*

* beneficial interest only

13. Total percentage holding of issued class following this notification

3.76%

14. Any additional information

Figures are based on shares in issue of 28,020,568

15. Name of contact and telephone number for queries

Jenny Owen
Tel: 01908 552600

16. Name and signature of authorised company official responsible for making this notification

Jenny Owen

Date of notification

22 May 2006

The FSA does not give any express or implied warranty as to the accuracy of this document or material and does not accept any liability for error or omission. The FSA is not liable for any damages (including, without limitation, damages for loss of business or loss of profits) arising in contract, tort or otherwise from the use of or inability to use this document, or any material contained in it, or from any action or decision taken as a result of using this document or any such material.

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Intisive Media partnership

Bepak PLC - Holding(s) in Company

Bepak PLC
30 May 2006

NOTIFICATION OF MAJOR INTERESTS IN SHARES

1. Name of company

BESPAK PLC

2. Name of shareholder having a major interest

BARCLAYS PLC THROUGH THE ENTITIES LISTED UNDER 4 BELOW

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18

n/a

4. Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them

Legal Entity	Holding	Percentage Held
Barclays Global Investors Ltd	938,022	3.3476
Barclays Life Assurance Co Ltd	85,443	0.3049
Gerrard Ltd	10,100	0.360
Barclays Capital Securities Ltd	89,338	0.3188
Group Holding	1,122,903	4.0073

5. Number of shares / amount of stock acquired

n/a

6. Percentage of issued class

n/a

7. Number of shares / amount of stock disposed

n/a

8. Percentage of issued class

n/a

9. Class of security

10p ordinary

10. Date of transaction

22 May 2006

11. Date company informed

30 May 2006

12. Total holding following this notification

1,122,903

13. Total percentage holding of issued class following this notification

4.0073

14. Any additional information

15. Name of contact and telephone number for queries

Jenny Owen
01908 525211

16. Name and signature of authorised company official responsible for making this notification

Company Secretary

Date of notification

30 May 2006

The FSA does not give any express or implied warranty as to the accuracy of this document or material and does not accept any liability for error or omission. The FSA is not liable for any damages (including, without limitation, damages for loss of business or loss of profits) arising in contract, tort or otherwise from the use of or inability to use this document, or any material contained in it, or from any action or decision taken as a result of using this document or any such material.

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bepak PLC - Directorate Change

Bepak PLC
02 June 2006

Bepak plc

Paul Boughton appointed Executive Director

Bepak plc ('Bepak'), a leader in the design and manufacture of medical devices for inhaled drug delivery and anaesthesia, is pleased to announce the appointment of Paul Boughton as Executive Director.

Paul joined Bepak in August 2005 as Corporate Development Director. Prior to that he was Business Development Director, and a member of the Board of Spectris plc. He is currently a non-executive director of Raymarine plc where he also chairs the audit committee. He was a non-executive director of London Bridge Software plc from 1999 to 2004.

Age 50, Paul has extensive financial and business development experience gained over 20 years in the area of high-tech manufacturing. Having graduated with a degree in business economics, Paul qualified as a chartered accountant with Deloitte Haskins & Sells before moving into industry.

Commenting on this appointment, John Robinson, Chairman, said:

'I am delighted to welcome Paul to the Board of Bepak. He has already made a significant contribution to the development of our business, and with his extensive and relevant experience I look forward to his contribution to the Board.'

Paul Boughton said:

'I am delighted to be joining the Board at such an exciting time for Bepak. The acquisition of King Systems has significantly diversified our revenues and provides an additional platform for growth, while the recently launched Exubera (R) device is the first to deliver inhaled insulin. I look forward to continuing to work closely with Mark Throdahl and the management team to help shape Bepak for continuing success.'

In accordance with Listing Rule 9.6.15, it is confirmed that there are no details to be disclosed pursuant to Listing Rule 9.6.13.

For further information please contact:

Bepak	
John Robinson, Chairman	Tel: +44 (0)20 7960 6320
Mark Throdahl, Chief Executive	Tel: + 44 (0)1908 552600

Maitland	
Brian Hudspith or Liz Morley	Tel: +44 (0)20 7379 5151

Bepak plc is a leader in specialty medical devices, developing delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings.

The company develops and manufactures a range of devices including metered dose inhalers, dry powder devices, actuators, compliance aids, disposable facemasks, breathing circuits and laryngeal tubes. The group holds the 2005 Frost & Sullivan Award for Technology Innovation and has facilities in King's Lynn and Milton Keynes in the UK, in Indianapolis, Indiana and Kent, Ohio, in the US and in Mumbai, India. Bepak is a public company quoted on the full list of the London Stock Exchange (LSE: BPK).

This information is provided by RNS
The company news service from the London Stock Exchange

investegate

a Financial Express and Inclusive Media partnership

Bepak PLC - Facility Visit

Bepak PLC
20 June 2006

Bepak hosts visit for major investors and sector analysts

Bepak plc ('Bepak'), a leader in the design and manufacture of medical devices for inhaled drug delivery and anaesthesia, is hosting a visit for major investors and sector analysts to its manufacturing facility in Milton Keynes on Wednesday 21 June 2006.

The purpose of the visit is to provide investors and analysts with:

- an overview of Bepak's business strategy;
- an opportunity to meet with senior and operational management from the UK and US;
- a presentation by the new general manager of King Systems, which Bepak acquired last December; and
- a tour of Bepak's manufacturing facility to see the production of the new Exubera(R) device.

The Company is in close period prior to the announcement of its preliminary results on 12 July 2006.

For further information please contact:

Bepak
Mark Throdahl, Chief Executive
Martin Hopcroft, Group Finance Director

Tel: +44 (0)1908 552600

Maitland
Brian Hudspith or Liz Morley

Tel: +44 (0)20 7379 5151

Bepak plc is a leader in specialty medical devices, developing delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings.

The company develops and manufactures a range of devices including metered dose inhalers, dry powder devices, actuators, compliance aids, disposable facemasks, breathing circuits and laryngeal tubes. The group holds the 2005 Frost & Sullivan Award for Technology Innovation and has facilities in King's Lynn and Milton Keynes in the UK, in Indianapolis, Indiana and Kent, Ohio, in the US and in Mumbai, India. Bepak is a public company quoted on the full list of the London Stock Exchange (LSE: BPK).

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bepak PLC - Holding(s) in Company

Bepak PLC
28 June 2006

NOTIFICATION OF MAJOR INTERESTS IN SHARES

1. Name of Company

Bepak plc

2. Name of shareholder having a major interest

Aviva plc and its subsidiaries

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non beneficial interest or in the case of a an individual holder if it is a holding of that person's spouse or children under the age of 18

As in 2 above

4. Name of each of the registered holder(s) and, if more than one holder, the number of shares held by each of them

Morley Fund Management Ltd	
BNY Norwich Union Nominees Limited	172,968*
Chase GA Group Nominees Limited	463,295*
Chase Nominees Limited	29,173*
CUIM Nominee Limited	148,689*
Vidacos Nominees Limited	14,816*

*denotes beneficial interest

5. Number of shares/amount of stock acquired

n/a

6. Percentage of issued class

n/a

7. Number of shares/amount of stock disposed

104,862

8. Percentage of issued class

0.37%

9. Class of security

Ordinary GBP 0.10 shares

10. Date of transaction

27 June 2006

11. Date Company informed

28 June 2006

12. Total following this notification

828,941*

* beneficial interest only

13. Total percentage holding of issued class following this notification

2.96%

14. Any additional information

Figures are based on shares in issue of 28,020,568

15. Name of contact and telephone number for queries

16. Name and signature of authorised company official responsible for making this notification

Jenny Owen
Company Secretary
01908 525211

Date of Notification 28 June 2006

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bespak PLC - Holding(s) in Company

Bespak PLC
30 June 2006

NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Name of Company

Bespak plc

2. Name of shareholder having a major interest

Barclays plc and its subsidiaries

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non beneficial interest or in the case of a an individual holder if it is a holding of that person's spouse or children under the age of 18

As in 2 above

4. Name of each of the registered holder(s) and, if more than one holder, the number of shares held by each of them

Barclays Bank plc		
Barclays Capital Securities Ltd	186,143	0.6643%
Barclays Life Assurance Co Ltd	101,295	0.3615%
Gerrard Ltd	10,100	0.360%
Barclays Global Investors Ltd	1,177,619	4.2027%
Group Holding	1,475,157	5.2645%
CUIM Nominee Limited	148,689	

5. Number of shares/amount of stock acquired

n/a

6. Percentage of issued class

n/a

7. Number of shares/amount of stock disposed

n/a

8. Percentage of issued class

n/a

9. Class of security

Ordinary GBP 0.10 shares

10. Date of transaction

27 June 2006

11. Date Company informed

30 June 2006

12. Total following this notification

1,475,157

13. Total percentage holding of issued class following this notification

5.2645%

14. Any additional information

Figures are based on shares in issue of 28,020,568

15. Name of contact and telephone number for queries

16. Name and signature of authorised company official responsible for making this notification

Jenny Owen
Company Secretary
01908 525211

Date of Notification 28 June 2006

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Invisive Media partnership

Bespak PLC - Final Results

Bespak PLC
12 July 2006

Bespak plc
Preliminary results for the 52 weeks ended 29 April 2006
An excellent year

Bespak plc (LSE: BPK), a leader in devices for inhaled drug delivery and anaesthesia, today announces its preliminary results for the 52 weeks ended 29 April 2006.

HIGHLIGHTS

- Revenue up 17% to £93.1m (2005: £79.4m).
- Profit before tax and special items up 24% to £13.5m (2005: £10.9m).
- Profit before tax increased to £13.7m (2005: £4.8m).
- Cash generated from operations up 25% to £17.8m (2005: £14.2m).
- Diluted earnings per share before special items up 15% to 35.4p (2005: 30.9p).
- Diluted earnings per share increased to 37.3p (2005: 8.5p).
- Final dividend maintained at 12.1p per share (2005: 12.1p), making full year dividend of 19.1p per share (2005: 19.1p).
- Exubera(R) for diabetes launched and inhalation device in production.
- Successful acquisition in December 2005 of King Systems, a specialist in single-use breathing circuits, face masks and laryngeal tubes for use in surgery and critical care settings, reduces dependence on pharmaceutical approvals.

Mark Throdahl, Bespak's Chief Executive, commented:

'Last year was excellent for Bespak. Performance in our core businesses in inhaled drug delivery exceeded expectations; Exubera(R), the first inhaled drug for diabetes was approved, providing a significant market opportunity; and King Systems was acquired and successfully integrated. We look forward with confidence.'

For further information, please contact:

Bespak plc
Mark Throdahl - Chief Executive
Martin Hopcroft - Group Finance Director

Tel: +44 (0) 1908 525241

Maitland
Brian Hudspith
Elizabeth Morley

Tel: +44 (0) 207 3795151

About Bespak plc

Bespak, a leader in devices for inhaled drug delivery and anaesthesia, develops delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings. Bespak's product range includes metered dose and dry powder inhalers, actuators, inflation valves, breathing circuits, disposable face masks and laryngeal tubes. The group, which has facilities in King's Lynn and Milton Keynes in the UK and Indianapolis, Indiana and Kent, Ohio, in the US, is quoted on the Official List of the London Stock Exchange (LSE: BPK). For more information, please visit www.bespak.com.

OVERVIEW

Bepak's financial year ending 29 April 2006 was excellent. All our core businesses performed ahead of plan. Exubera(R), the first inhaled drug for diabetes, was approved, opening up significant annual sales potential. The Company acquired King Systems in December and delivered the first step of its strategy to reduce its dependency on pharmaceutical approvals.

Revenue, operating profit and diluted earnings per share all increased at double digit rates. Revenue increased by 17% to £93.1 million (2005: £79.4 million), operating profit before special items increased by 34% to £14.2 million (2005: £10.6 million), and diluted earnings per share before special items increased by 15% to 35.4p (2005: 30.9p). This strong financial performance was driven by growth in metered dose inhalation (MDI) valves, the commencement of manufacturing of the Exubera(R) inhaler, and the impact of the King Systems acquisition which from December 2005 contributed £11.1 million of sales.

The Board has proposed a final dividend of 12.1p per share (2005: 12.1p), making a full year dividend of 19.1p per share (2005: 19.1p). This is supported by the Group's strong operating cash flow during the year, which increased 25% to £17.8 million (2005: £14.2 million). Net debt as at 29 April was £27.8 million (2005: £17.4 million net cash), reflecting the impact of new borrowings to finance the King acquisition and payment of a one-off contribution of £9.0 million to the pension scheme.

In June, Bepak received an unprecedented three awards from the British Plastics Federation, which recognised our position as a world-class manufacturer of disposable medical devices. The Company won 'Best Health & Safety Programme', 'Best Environmental or Energy Efficiency Programme' and the coveted 'Processor of the Year' awards. The citation described Bepak as 'an extremely well-run multinational operation that has built an enviable business reputation through strong product niches that have enabled it to continue to strongly grow its business'.

OPERATIONAL REVIEW

Last year, we articulated a strategy to build a consistent revenue and earnings track record. We aim to achieve this goal through organic growth, selective acquisitions and three competencies - Six Sigma manufacturing, proprietary development processes, and high-performance culture - which we will apply to our own existing businesses and bring to future acquisitions. We said that we would broaden the Group's customer base beyond pharmaceutical companies and reduce our dependency on lengthy development programmes which make growth difficult to forecast. We said that the anticipated approval of Exubera(R) for diabetes would have a significant impact on the Group.

These things have happened. Our Inhaled Drug Delivery business delivered double-digit sales growth in MDI valves and benefited from first production of the Exubera(R) inhaler. We delivered the first step of our diversification strategy by acquiring King Systems, which has been successfully integrated. Our Six Sigma programme delivered substantial savings and is creating a high performance culture at Bepak.

Having acquired King Systems, we now have three business segments: Inhaled Drug Delivery, Anaesthesia & Respiratory Care, and Consumer Dispensers.

Inhaled Drug Delivery

Bepak's Inhaled Drug Delivery segment consists of Respiratory and Device & Manufacturing Services, which are product groups with common customers, similar financial returns and shared facilities in King's Lynn and Milton Keynes. Sales increased by 3% to £76.5 million (2005: £74.0 million) as a result of increased volumes of HFA valves to European customers and the commencement of manufacturing of the Exubera(R) inhaler, partially offset by the loss of revenue from the closure of our North Carolina facility in September 2005. Respiratory sales increased by 7% to £43.2 million (2005: £40.2 million) whilst Device & Manufacturing Services sales decreased by 1% to £33.3 million (2005: £33.8 million). Operating profit before special items increased by 13% to £13.1 million (2005: £11.6 million), reflecting improved margins.

Respiratory

Bepak develops, manufactures and sells proprietary inhalation devices, including MDI valves, actuators and accessories to deliver pharmaceuticals to the lungs and nose. These products, which are based on Bepak's extensive intellectual property portfolio, play a critical role in the delivery system for drugs treating asthma and chronic obstructive pulmonary disease (COPD). MDI valves typically are customised and sole-sourced for each drug. Switching costs

are extremely high, and we sell the products as long as the drug is marketed.

Two drivers in the MDI market are the transition from chlorofluorocarbon (CFC) propellant to hydrofluoroalkane (HFA) and the shift of volume from proprietary to generic drugs.

The Montreal Protocol ozone depletion agreement requires that CFC propellant is replaced with HFA. This requires re-formulating the drug, new clinical trials, and submission of a new drug filing. Europe has largely converted to HFA formulations. Historically, Bepak has benefited from this conversion. Over the past four years we have become the MDI market leader by value, with the largest array of CFC and HFA valves, formulations and customers. We believe that we have won more than two-thirds of the HFA formulations approved around the world, including three HFA formulations in the USA. Last year, Bepak's HFA unit sales grew by 40% while CFC valve volumes fell by 29%. Overall MDI valve volumes grew by 4%.

In addition to HFA volume growth, generic customers have grown from 39% of Bepak's volume in 2003 to 60% today. Generic customers value responsiveness and flexible manufacturing. Bepak's strong performance during the HFA transition has in part been due to our strategy of providing outstanding technical support during development.

In March 2005, the FDA announced that the US albuterol market must convert to HFA by the end of 2008, which has inaugurated a period of significant change. Bepak enjoys a high share of the CFC albuterol market in the US, and none of the four approved HFA albuterol pharmaceutical suppliers currently has any meaningful market share. Bepak's customer base in CFC albuterol formulations differs from that in HFA equivalents, and its share of the market is expected to be rebased through this transition. In due course, this transition will lead to the cessation of manufacturing of CFC valves and allow Bepak to simplify its operations and achieve manufacturing economies.

Bepak's MDI valves are protected by numerous patents, including the rubber seals which are in constant contact with the drug. In order to support Bepak's proprietary HFA valve elastomer formulations, we have completed the construction phase of our investment in a captive elastomer development and manufacturing facility in King's Lynn. Manufacturing processes are now undergoing validation and customer approval. This new plant will protect both the supply chain for these critical components and the intellectual property associated with them.

Bepak is developing a portfolio of dose counters, which enable patients to monitor the number of doses remaining in their inhaler. We have developed our own proprietary dose counter for the US market, which has been pre-production sampled and is on test at a number of customers. In March, we signed a co-marketing and manufacturing agreement with Bang & Olufsen Medicom, who have developed a dose counter that requires reduced actuation force.

Device & Manufacturing Services

Bepak provides a comprehensive range of device-related services to pharmaceutical and drug delivery companies and operates the largest clean room in the UK. The business enjoyed double-digit sales growth from both our largest contract manufactured product as well as Innovata's ClickhalerTM device, under license to Otsuka Pharmaceutical Co. and Merck Generics. In August 2005, we commenced production of a dry powder inhaler for Chiesi Farmaceutici.

In January, Pfizer announced the approval of Exubera(R) in Europe and the USA, and which is now being launched. Production demand is ahead of our original expectations and the primary risk and opportunity we face in this business is the pace of Exubera(R)'s production scale-up.

Bepak's strategy is to broaden the portfolio of device development programmes, targeting high value opportunities that play to the Company's strengths in GMP programme management, precision plastic moulding and high volume automated assembly.

Over the past several years, we have developed a reputation for responsiveness and, as a result, our portfolio has more than doubled over the past three years to more than 12 active programmes. Last year, we won two new programmes, including a specialty device for a leading global pharmaceutical company and Caretek's Implaject device.

Anaesthesia & Respiratory Care

King Systems develops, manufactures and sells single-use breathing circuits, face masks and laryngeal tubes for use in surgery and critical care settings.

These products are manufactured in facilities in Indianapolis, Indiana and Kent, Ohio. Unlike Bespak's other products, these products are sold to anaesthetists by our own 35-person sales force, which calls on hospitals and pulls the products through medical/surgical distributors. Sales for the four months ending 29 April were £11.1 million. Operating profit before special items was £2.0 million, representing the maiden contribution from the acquisition of King Systems, after group allocations.

The King Systems acquisition represents an expansion into a business adjacent to Bespak's Inhaled Drug Delivery segment, with complementary products, manufacturing and profitability. It strengthens Bespak's footprint in the large US market. The consideration for King Systems is \$95 million, which consisted of an initial payment of \$75 million, \$10 million paid on exceeding \$9.3 million of adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation) for the year ended 31 December 2005 and another \$10 million payable on attaining \$11.0 million adjusted EBITDA for the year ended 31 December 2006.

King Systems estimates that its sales on a hospital level are up 10% from the prior year. Growth has been driven by three new products:

- The Universal F2 breathing circuit is a patented, dual limb circuit which is compact when stored but can be expanded during use. It can be shaped to avoid the surgical field and retains that shape during surgical procedures.
- King's laryngeal tubes are available in both reusable and disposable designs. They offer superior positive pressure ventilation relative to laryngeal masks, are superior to endotracheal tubes in terms of ease of use and lower drug delivery costs.
- King recently launched the Airtraq(R) device, which is the first disposable optical laryngoscope. Airtraq(R) is used for difficult endotracheal tube intubations and, together with the laryngeal tubes, broadens King Systems' airway management offering.

King's five senior managers have all been retained since the acquisition. Immediately after the acquisition, the Vice President of Sales & Marketing was named President following the retirement of King's founder and CEO. A new Vice President of Finance has been recruited who reports jointly to the President and Bespak's Group Finance Director.

The key risk facing King is maintaining certain Group Purchasing Organisation contracts as well as absorbing the impact of raw material cost increases similar to those seen in Bespak's other businesses.

Consumer Dispensers

Bespak manufactures pumps for consumer household products, toiletries and fragrances. Sales increased 3% to £5.5 million (2005: £5.4 million) and operating losses decreased to £1.0 million (2005: £1.1 million). Its market remains competitive, although the recent launch of a new product is gaining considerable traction with several large European customers. The BK580 fine mist spray pump was launched in March. It has a number of advantages, including 10% smaller mean particle size and a greatly reduced output of large spray particles. It handles viscous formulations unusually well and produces a highly symmetrical size distribution with smooth rounded patterns.

Growth Strategy & Acquisitions

Over the past year, we have confirmed our strategy to grow organically and through selective acquisitions. Furthermore, we have deepened competencies in Six Sigma and GMP product development, whilst promoting a high-performance culture. We believe this strategy is working. Following the successful King acquisition, it is our intention to look for further acquisitions in the anaesthesiology and respiratory products industry, while also considering acquisitions that complement our inhaled drug delivery businesses.

FINANCIAL REVIEW

Trading

Revenue increased by 17% to £93.1 million (2005: £79.4 million), of which the majority of the growth was generated by the acquisition of King Systems Corporation in December 2005.

Geographically, sales outside the UK now account for 74% (2005: 70%) of revenue despite the fact that 81% (2005: 78%) of sales originate in the UK.

Expenditure on research and development, which increased by 19% to £3.8 million

(2005: £3.2 million), was expensed as incurred rather than capitalised, since it is not possible to demonstrate with sufficient certainty that projects will be commercially viable prior to customer and regulatory approval. Excluding the acquisition, underlying expenditure on research and development increased by 14%.

Operating profit before special items increased by 34% to £14.2 million (2005: £10.6 million) reflecting growth in operating margins to 15% (2005: 13%), together with an initial contribution from the acquisition of King Systems Corporation. Excluding the acquisition, underlying operating profit before special items increased by 15% on sales that increased by 3%.

Certain special items have been separately reported in order to present a more balanced perspective of the underlying trading performance. Firstly, as a result of the ability to sell the building and certain plant and equipment at prices higher than anticipated together with reduced closure costs, exceptional operating income of £0.9 million was booked in our US manufacturing operation in North Carolina. Secondly, there is an amortisation charge of £0.7 million on the intangible assets acquired with King Systems Corporation.

After special items, operating profit increased to £14.4 million (2005: £4.5 million).

The acquisition of King Systems Corporation was financed largely by debt, such that there is a net finance cost of £0.7 million (2005: £0.3 million net finance income) from a partial year of financing the acquisition. The financing expense has been largely fixed in the medium term with an interest rate swap.

Profit before tax and special items increased by 24% to £13.5 million (2005: £10.9 million). After special items, profit before tax increased to £13.7 million (2005: £4.8 million).

Tax

The underlying tax charge on profit before tax and special items of 27% (2005: 23%) has benefited from the financial structuring of the acquisition as well as utilisation of losses from the closure of the US manufacturing facility.

After the non-cash tax credit of £0.3 million (2005: £nil) on the amortisation of acquired intangible assets, the overall tax charge of 25% (2005: 52%) reflects the nil tax charge on the exceptional credit. The tax charge last year reflected the nil tax credit on the exceptional operating expenses.

Earnings per share

Diluted earnings per share before special items increased by 15% to 35.4p (2005: 30.9p) reflecting a modestly increased tax charge in view of the change in geographic mix of activities. After special items, diluted earnings per share increased to 37.3p (2005: 8.5p).

Dividends

The Board is recommending a maintained final dividend per share of 12.1p (2005: 12.1p), such that the total dividend for the year amounts to 19.1p (2005: 19.1p). The final dividend will be paid on 26 October 2006 to shareholders on the register on 6 October 2006. Dividend cover, based on earnings before special items, increased to 1.9 times (2005: 1.6 times).

Goodwill and intangible assets

Upon acquisition of King Systems Corporation, intangible assets are required to be capitalised and amortised over their useful lives. Goodwill, being the difference between purchase consideration and net assets (including intangible assets), is required to be capitalised and not amortised. At the year end, the carrying value of goodwill (£39.3 million) and intangible assets (£14.9 million) were reviewed and no impairment was required.

Cash Flow

Trading finished strongly last year, and inventories have increased to scale-up for manufacture of the Exubera(R) inhaler and to plan for the phase out of CFC albuterol formulations in the US. Nevertheless, cash generated from operations increased by 25% to £17.8 million (2005: £14.2 million), which was after a cash outflow of £1.7 million for the exceptional costs on closure of the US manufacturing facility.

There was a cash outflow of £45.8 million for the acquisition of King Systems

Corporation, together with a cash outflow of £9.5 million reflecting clearance of the acquisition with the Pensions Regulator to fund the deficit in the defined benefit pension scheme. These were financed by existing cash resources and £20.1 million of new loans. There are further payments of up to £6.2 million payable to the vendors of King Systems Corporation, mainly dependent on its financial performance in calendar 2006.

In the past few years, capital expenditure has been well below the level of capital replacement in view of significant investments in earlier years. Going forward, capital expenditure is expected to reflect the level appropriate for capital replacement. However, there are increasing numbers of customer projects, both current and prospective, in Inhaled Drug Delivery that may warrant a stepped increase in capacity in the medium term.

Treasury

At the year end, the Group had net debt of £27.8 million (2005: £17.4 million net cash) and undrawn committed facilities of £25.5 million (2005: £12.8 million).

Transactions in foreign currencies are matched wherever possible and the net position is hedged using forward contracts. A significant proportion of operating and intangible assets are denominated in US dollars, which are largely matched by US dollar borrowings, thereby hedging the balance sheet exposure. Translation effects of exchange rate movements on the income statement are not hedged. The treasury function does not act as a profit centre and speculative treasury transactions are not undertaken.

Debt financing for the acquisition has improved the capital efficiency and will require continued discipline in financial management.

Last year, the average rate of exchange between sterling and the US dollar was 1.78 (2005: 1.85), whilst the year end rate of exchange was 1.82 (2005: 1.91).

Pensions

Bespak operates a defined benefit pension scheme in the UK that is closed to new employees, who are eligible to join a defined contribution pension scheme. During the year, the company negotiated with the trustees and obtained clearance of the acquisition with the Pensions Regulator to fund the deficit of £15.6 million under FRS 17 as at 30 April 2005 by an initial payment of £9.0 million in December 2005 and with the balance of the deficit settled by equal monthly installments over 5 years.

As at 29 April 2006, the deficit was £12.0 million under IAS 19 and the company is in dialogue with the trustees to agree a schedule of contributions in respect of the revised deficit.

International Financial Reporting Standards

These results for the 52 weeks ended 29 April 2006 are prepared under International Accounting Standards and International Financial Reporting Standards (IFRS) as adopted by the European Union. The adoption of IFRS represents an accounting change and does not affect the underlying operations or cash flows, although implementation of the new standards may result in increased volatility in reported results.

OUTLOOK

Last year, the business benefited from several positive developments: the closure of the US manufacturing facility followed by the acquisition of King Systems Corporation and commencement of manufacturing for the Exubera(R) inhaler.

Looking ahead, a number of key issues will influence Bepak's performance:

- Manufacturing will continue to be scaled-up for the Exubera(R) inhaler to support its global launch, with production activity expected to be ahead of our original expectations, although it will be some months before end-user demand is ascertained.
- There will be a full year trading benefit from the King acquisition compared to four months last year, and we anticipate growth with the added benefit of new products.
- The conversion from CFC to HFA in albuterol formulations in the US is accelerating, generating higher than expected levels of activity in the short term, but is expected to create uncertainty from the start of the next calendar year. Bepak enjoys a high share of the CFC albuterol market in the

US, and its customer base in CFC albuterol formulations differs from that in HFA equivalents, and its share of the market is expected to be rebased through this transition.

The Board remains confident of meeting its expectations for the current financial year.

12 July 2006

Consolidated Income Statement
For the 52 weeks ended 29 April 2006

		2006 Before special items	2006 Special items (Note 3)	2006 Total	2005 Before special items	2005 Special items (Note 3)	2005 Total
	Note	£000	£000	£000	£000	£000	£000
Revenue	2	93,084	-	93,084	79,386	-	79,386
Operating expenses		(78,902)	242	(78,660)	(68,831)	(6,066)	(74,897)
Operating profit	2	14,182	242	14,424	10,555	(6,066)	4,489
Finance income		825	-	825	894	-	894
Finance expenses		(1,030)	-	(1,030)	(157)	-	(157)
Other finance costs		(501)	-	(501)	(393)	-	(393)
Share of post tax profits/ (losses) of associate		10	-	10	(17)	-	(17)
Profit before tax		13,486	242	13,728	10,882	(6,066)	4,816
Taxation	4	(3,696)	290	(3,406)	(2,498)	-	(2,498)
Profit for the financial period		9,790	532	10,322	8,384	(6,066)	2,318
Basic earnings per share	5	35.9p	2.0p	37.9p	31.3p	(22.6p)	8.7p
Diluted earnings per share	5	35.4p	1.9p	37.3p	30.9p	(22.4p)	8.5p
Dividends per share	6			19.1p			19.1p

All amounts relate to continuing operations.

Consolidated Balance Sheet
At 29 April 2006

Note	2006 £000	2005 £000
------	--------------	--------------

Non-current assets			
Property, plant and equipment		52,537	51,159
Goodwill	7	39,259	-
Other intangible assets	8	14,906	130
Investment in associates		269	269
Available-for-sale financial assets		-	77
		-----	-----
		106,971	51,635
		-----	-----
Current assets			
Inventories		9,571	6,082
Trade and other receivables	9	19,289	14,704
Current taxation receivable		282	-
Cash and cash equivalents	10	9,782	20,302
		-----	-----
		38,924	41,088
		-----	-----
Current liabilities			
Borrowings	10	(23,106)	(2,887)
Trade and other payables		(15,080)	(11,621)
Current taxation payable		(3,850)	(1,618)
Provisions and other liabilities		(6,147)	(2,054)
		-----	-----
		(48,183)	(18,180)
		-----	-----
Net current (liabilities)/assets		(9,259)	22,908
Non-current liabilities			
Borrowings	10	(14,449)	-
Deferred taxation		(5,197)	(443)
Defined benefit pension scheme deficit	11	(12,002)	(15,703)
Other non-current liabilities		-	(399)
		-----	-----
		(31,648)	(16,545)
		-----	-----
Net assets	2	66,064	57,998
		=====	=====
Shareholders' equity			
Share capital		2,802	2,681
Share premium		28,837	23,051
Retained earnings		34,693	32,509
Other reserves		(268)	(243)
		-----	-----
Total equity	12	66,064	57,998
		=====	=====

The preliminary financial statements were approved by the Board on 11 July 2006

Consolidated Cash Flow Statement
For the 52 weeks ended 29 April 2006

	Note	2006 £000	2005 £000
Cash flows from operating activities			
Operating profit before taxation		14,424	4,489
Depreciation		7,072	7,450
Amortisation		750	187
(Profit)/loss on disposal of property, plant and equipment		(272)	97
Share based payments		410	364
Impairment (credit)/charge		(438)	3,784
Increase in inventories		(1,506)	(171)
Increase in trade and other receivables		(789)	(4,169)
Increase in trade and other payables		21	322
(Decrease)/increase in provisions		(2,140)	1,887
Decrease in financial instruments		(149)	(124)
Increase in defined benefit pension scheme provisions		415	-
Provision against fixed asset investment		-	102
		-----	-----

Cash generated from operations		17,798	14,218
Interest paid		(854)	(157)
Tax paid		(3,554)	(2,608)
		-----	-----
Net cash inflow from operating activities		13,390	11,453
		-----	-----
Cash flows from investing activities			
Purchases of property, plant and equipment		(4,334)	(2,590)
Purchases of intangible assets		(182)	-
Proceeds from sale of property, plant and equipment		3,402	4
Disposal of fixed asset investments		83	66
Interest received		815	900
Dividend received from associate		10	-
Acquisition of subsidiary (net of cash acquired)	13	(45,772)	-
		-----	-----
Net cash used in investing activities		(45,978)	(1,620)
		-----	-----
Cash flows from financing activities			
Net proceeds from issue of ordinary share capital		403	12
Equity dividends paid to shareholders	6	(5,201)	(5,111)
New bank loans raised		20,121	-
Repayment of amounts borrowed		(1,008)	-
Payments to fund defined benefit pension scheme deficit	11	(9,540)	-
		-----	-----
Net cash generated/(used) in financing activities		4,775	(5,099)
		-----	-----
Net (decrease)/increase in cash and short-term borrowings		(27,813)	4,734
Effects of exchange rate changes		932	361
Cash and short-term borrowings at start of period		17,415	12,320
		-----	-----
Cash and short-term borrowings at end of period	10	(9,466)	17,415
		=====	=====

Consolidated Statement of Recognised Income and Expense
For the 52 weeks ended 29 April 2006

	2006	2005
	£000	£000
Fair value movements on cash flow hedges	152	-
Deferred tax on fair value movements on cash flow hedges	(46)	-
Exchange movements on translation of foreign subsidiaries	(331)	(142)
Deferred tax on exchange movements	99	-
Deferred tax on share based payments	193	21
Actuarial losses on defined benefit pension scheme	(5,040)	(2,547)
Current tax on actuarial losses	543	-
Deferred tax on actuarial losses	970	765
	-----	-----
Net loss recognised directly in equity	(3,460)	(1,903)
Profit for the financial period	10,322	2,318
	-----	-----
Total recognised income for the period	6,862	415
	=====	=====

Notes to the accounts

1. Basis of preparation

The preliminary announcement for the 52 weeks ended 29 April 2006 has been prepared in accordance with International Accounting Standards and International Financial Reporting Standards (IFRS) as adopted by the European Union (EU) at 29 April 2006. On 13 January 2006, the Group reported on the impact of IFRS on its results for the 52 weeks ended 30 April 2005 including the most significant accounting policies. Details are provided in the document 'Adoption of International Financial Reporting Standards (IFRS)' that is available on the

Group's website (www.bepak.com) or from the Company Secretary.

The financial information in this preliminary announcement does not constitute the Company's statutory accounts for the 52 weeks ended 29 April 2006 or the 52 weeks ended 30 April 2005, but is derived from those accounts. Statutory accounts for 2005, which were prepared under accounting practices generally accepted in the UK, have been delivered to the Registrar of Companies and those for 2006 will be delivered after the Company's Annual General Meeting. The auditors have reported on those accounts; their reports were unqualified and did not contain statements under s237(2) or s237(3) Companies Act 1985.

2. Segmental information

Revenue by business segment	2006 £000	2005 £000
Inhaled Drug Delivery	76,502	74,009
Consumer Dispensers	5,524	5,377
Anaesthesia & Respiratory Care	11,118	-
	-----	-----
Sales	93,144	79,386
Intra-segmental sales	(60)	-
	=====	=====
Revenue	93,084	79,386
	=====	=====

Revenue by origin	2006 £000	2005 £000
United Kingdom	78,092	67,882
United States of America	17,802	18,923
	-----	-----
Sales	95,894	86,805
Intra-segmental sales	(2,810)	(7,419)
	-----	-----
Revenue	93,084	79,386
	=====	=====

Revenue by destination	2006 £000	2005 £000
United Kingdom	23,796	23,613
United States of America	41,982	27,808
Europe	19,852	20,276
Rest of the World	7,454	7,689
	-----	-----
Revenue	93,084	79,386
	=====	=====

Operating profit by business segment	2006 Before Special Items £000	2006 Special items (Note 3) £000	2006 Total £000
Inhaled Drug Delivery	13,125	901	14,026
Consumer Dispensers	(962)	-	(962)
Anaesthesia & Respiratory Care	2,019	(659)	1,360
	-----	-----	-----
Operating profit	14,182	242	14,424
	=====	=====	=====

2. Segmental information (continued)

Operating profit by business segment	2005 Before Special Items £000	2005 Special items (Note 3) £000	2005 Total £000
Inhaled Drug Delivery	11,644	(6,066)	5,578

Consumer Dispensers	(1,089)	-	(1,089)
Anaesthesia & Respiratory Care	-	-	-
	-----	-----	-----
Operating profit	10,555	(6,066)	4,489
	=====	=====	=====

Net assets by business segment	2006	2005
	£000	£000
Inhaled Drug Delivery	52,903	53,586
Consumer Dispensers	4,240	4,415
Anaesthesia & Respiratory Care	63,231	-
Unallocated net liabilities	(54,310)	(3)
	-----	-----
Net assets	66,064	57,998
	=====	=====
Exchange rates	2006	2005
Average rate of exchange US\$: £1	1.78	1.85
Closing rate of exchange US\$: £1	1.82	1.91

3. Special items

	2006	2005
	£000	£000
Exceptional operating income/(expenses)	901	(6,066)
Amortisation of acquired intangible assets	(659)	-
	-----	-----
Special items before tax	242	(6,066)
Taxation on amortisation of acquired intangible assets	290	-
	-----	-----
Special items after tax	532	(6,066)
	=====	=====

The exceptional operating income in the 52 weeks ended 29 April 2006 comprised the reversal of closure provisions and impairment provisions against the carrying value of the Group's fixed assets in the United States following closure of the manufacturing facility in North Carolina. Amortisation represents the charge for other intangible assets acquired with King Systems. The tax credit represents that related to the amortisation charge. The exceptional operating expenses in the 52 weeks ended 30 April 2005 comprised an impairment charge for the land, buildings, plant and equipment, together with a provision for closure costs, on which there was no tax impact.

4. Taxation

	2006	2005
	£000	£000
Current income tax	3,905	2,923
Deferred income tax	(499)	(425)
	-----	-----
	3,406	2,498
	=====	=====

5. Earnings per share

	2006	2005
	£000	£000
Net profit after tax before special items attributable to ordinary shareholders	9,790	8,384
Special items after taxation	532	(6,066)
	-----	-----
Net profit after tax attributable to ordinary shareholders	10,322	2,318
	-----	-----
Weighted average number of shares in issue (shares)	27,242,663	26,805,889
Weighted average number of shares owned by ESOT (shares)	(8,071)	(34,114)
	-----	-----
Average number of ordinary shares in issue for basic earnings (shares)	27,234,592	26,771,775
Dilutive impact of share options outstanding		

(shares)	422,960	353,691
	-----	-----
Diluted average number of ordinary shares in issue (shares)	27,657,552	27,125,466
	-----	-----
Basic earnings per share before special items (pence)	35.9p	31.3p
Basic profit/(loss) per share on special items (pence)	2.0p	(22.6p)
	-----	-----
Basic earnings per share (pence)	37.9p	8.7p
	=====	=====
Diluted earnings per share before special items (pence)	35.4p	30.9p
Diluted profit/(loss) per share on special items (pence)	1.9p	(22.4p)
	-----	-----
Diluted earnings per share (pence)	37.3p	8.5p
	=====	=====

6. Dividends

	2006	2005
	£000	£000
Final dividend paid for 2005 of 12.1p per share (2005: 12.1p per share)	3,241	3,237
Interim dividend paid for 2006 of 7.0p per share (2005: 7.0p per share)	1,960	1,874
	-----	-----
	5,201	5,111
	=====	=====

A final dividend of 12.1p per share for the 52 weeks ended 29 April 2006 is to be proposed for approval at the Annual General Meeting and which will utilise an estimated £3.4m of shareholders' equity. It will be paid on 26 October 2006 to shareholders on the register on 6 October 2006.

7. Goodwill

	£000
At 1 May 2005	-
Additions through acquisition (note 13)	40,966
Effects of exchange rate changes	(1,707)

At 29 April 2006	39,259

8. Other intangible assets

	£000
At 1 May 2005	130
Additions	182
Additions through acquisition (note 13)	16,000
Transfer from property, plant and equipment	18
Amortisation	(750)
Effects of exchange rate changes	(674)

At 29 April 2006	14,906

9. Trade and other receivables

	2006	2005
	£000	£000
Trade and other receivables falling due within one year	19,064	13,838
Trade and other receivables falling due after more than one year	225	866
	-----	-----
	19,289	14,704
	=====	=====

10. Reconciliation of net cash flow to movement in net debt

	Cash and cash equivalents £000	Current borrowings £000	Non-current borrowings £000	Net cash/(debt) £000
At 1 May 2005	20,302	(2,887)	-	17,415
Cash flow for the period	(10,504)	(17,309)	-	(27,813)
New long-term bank debt raised		(4,024)	(16,097)	(20,121)
Debt repayments included in cash flow for the period	-	-	1,008	1,008
Finance lease acquired	-	(7)	(9)	(16)
Effect of exchange rate changes	(16)	1,121	649	1,754
	-----	-----	-----	-----
At 29 April 2006	9,782	(23,106)	(14,449)	(27,773)
	=====	=====	=====	=====
Net debt at 29 April 2006 comprises:				
Cash and short-term borrowings	9,782	(19,248)	-	(9,466)
Bank term loan	-	(3,851)	(14,442)	(18,293)
Finance lease obligations	-	(7)	(7)	(14)
	-----	-----	-----	-----
At 29 April 2006	9,782	(23,106)	(14,449)	(27,773)
	=====	=====	=====	=====

Cash flow includes an outflow of £1,687,000 in the 52 weeks ended 29 April 2006 and an outflow of £235,000 in the 52 weeks ended 30 April 2005 relating to exceptional operating income/expenses.

11. Defined benefit pension scheme deficit

	2006 £000	2005 £000
Pension deficit at start of period	15,703	12,773
Current service costs	1,537	1,281
Expected return on plan assets	(1,657)	(1,505)
Interest cost	2,041	1,898
Actuarial losses	5,040	2,547
Regular employer contributions	(1,122)	(1,291)
Employer payments to fund defined benefit pension scheme deficit	(9,540)	-
	-----	-----
Pension deficit at end of period	12,002	15,703
	=====	=====

12. Consolidated Statement of Changes in Shareholders' Equity

	2006 £000	2005 £000
Total equity at start of period	57,998	62,318
Total recognised income for the period	6,862	415
Recognition of share-based payments	410	364
Proceeds from sale of shares for employee options	314	-
Proceeds from release of own shares held	88	12
Equity dividends	(5,201)	(5,111)
Issue of share capital as part of consideration for acquisition of subsidiary	5,593	-
	-----	-----
Total equity at end of period	66,064	57,998
	=====	=====

13. Acquisition

On 22 December 2005, the group purchased 100% of the shares of King Systems Corp ('King') for total consideration and acquisition costs of £57.7m. This purchase has been accounted for as an acquisition. From the date of acquisition to 29 April 2006, King contributed £11.1m to turnover, £2.0m to operating profit before special items and £1.4m to profit before tax. King contributed £2.3m to the group's net operating cash flows, paid £0.6m in respect of taxation and utilised £0.3m for capital expenditure. Intangible fixed assets were recognised at their respective fair values where these could be measured reliably. The

residual excess over the net assets acquired is recognised as goodwill in the financial statements.

	Carrying values pre- acquisition £000	Fair value adjustments £000	Provisional fair values £000
Other intangible assets	-	16,000	16,000
Property, plant and equipment	5,031	1,764	6,795
Inventories	2,003	-	2,003
Receivables	3,688	-	3,688
Payables	(2,831)	-	(2,831)
Current taxation	(187)	(2,122)	(2,309)
Deferred taxation	294	(7,034)	(6,740)
Cash and cash equivalents	189	-	189
Lease obligations	(16)	-	(16)
Net assets acquired	8,171	8,608	16,779
Goodwill			40,966
Total consideration			57,745
Total consideration satisfied by:			
Ordinary shares issued			5,593
Cash			43,090
Net asset adjustment paid in May 2006			833
Deferred contingent consideration			5,358
Directly attributable costs			2,871
Total consideration			57,745

The fair value adjustments contain some provisional amounts which are subject to finalisation within 12 months of the date of acquisition. Shares issued were valued at market price at the date of acquisition. Goodwill represents the value of synergies and the assembled work force.

The outflow of cash and cash equivalents on the acquisition of King is calculated as follows:

	£000
Cash consideration	43,090
Directly attributable costs	2,871
Cash outflow	45,961
Cash acquired	(189)
Net cash impact	45,772

The other intangible assets acquired as part of the acquisition of King can be analysed as follows:

	£000
Patented and unpatented technology and know-how	5,122
Trademarks and trade names	4,703
Customer contracts and relationships	2,999
Distribution agreements	3,176
Other intangible assets	16,000

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bespak PLC - Director/PDMR Shareholding

Bespak PLC
13 July 2006

NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS

This form is intended for use by an issuer to make a RIS notification required by DR 3.1.4R(1).

- (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.
- (2) An issuer making a notification in respect of a derivative relating to the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.
- (3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.
- (4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

Please complete all relevant boxes in block capital letters.

1. Name of the issuer

BESPAK PLC

2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or

(ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or

(iii) both (i) and (ii)

both

3. Name of person discharging managerial responsibilities/director

CHRIS BANKS (DIRECTOR)

4. State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

N/A

5. Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest

THE NOTIFICATION IS IN RESPECT OF HOLDINGS OF THE PERSON REFERRED TO IN 3 ABOVE

6. Description of shares (including class), debentures or derivatives or financial instruments relating to shares

ORDINARY SHARES OF 10p EACH

7. Name of registered shareholders(s) and, if more than one, the number of

shares held by each of them

CHRIS BANKS

8. State the nature of the transaction

PURCHASE OF ORDINARY SHARES

9. Number of shares, debentures or financial instruments relating to shares acquired

4,000

10. Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.01%

11. Number of shares, debentures or financial instruments relating to shares disposed

N/A

12. Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

N/A

13. Price per share or value of transaction

£6.17 PER SHARE

14. Date and place of transaction

13 JULY 2006
LONDON

15. Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

10,000 ORDINARY SHARES (0.036%)

16. Date issuer informed of transaction

13 JULY 2006

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

17. Date of grant

N/A

18. Period during which or date on which it can be exercised

N/A

19. Total amount paid (if any) for grant of the option

N/A

20. Description of shares or debentures involved (class and number)

N/A

21. Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

N/A

22. Total number of shares or debentures over which options held following notification

N/A

23. Any additional information

NONE

24. Name of contact and telephone number for queries

COMPANY SECRETARY

Name and signature of duly authorised officer of issuer responsible for making notification

JENNY OWEN

Date of notification

13 JULY 2006

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Exclusive Media partnership

Bepak PLC - Holding(s) in Company

Bepak PLC
14 July 2006

NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Name of Company
Bepak plc

2. Name of shareholder having a major interest
Schroders plc and its subsidiaries

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non beneficial interest or in the case of a an individual holder if it is a holding of that person's spouse or children under the age of 18

As in 2 above

4 Name of each of the registered holder(s) and, if more than one holder, the number of shares held by each of them

Registered Holder	Amount
Chase Manhattan Bank	119,610
British Coal Staff Superannuation a/c;P	992,866
Chase Nominees Limited	150,000
Mineworkers' Pension Scheme a/c: R	1,037,240
Nortrust Nominees Limited	225,000
	2,524,716
Schroder Unit Trusts Limited and registered in the name of Chase Nominees Limited	2,752,904
TOTAL	5,277,620

5. Number of shares/amount of stock acquired
n/a

6. Percentage of issued class
n/a

7 Number of shares/amount of stock disposed
n/a

8. Percentage of issued class

9. Class of security
Ordinary GBP 0.10 shares

10. Date of transaction
10 July 2006

11. Date Company informed
11 July 2006

12. Total following this notification
5,277,620

13. Total percentage holding of issued class following this notification
18.992%

14. Any additional information
Figures are based on shares in issue of 28,020,568

15. Name of contact and telephone number for queries

16. Name and signature of authorised company official responsible for making this notification

Jenny Owen

Company Secretary

01908 525211

Date of Notification 11 July 2006

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bepak PLC - Blocklisting

Bepak PLC
25 July 2006

SCHEDULE 5

BLOCKLISTING SIX MONTHLY RETURN

1. Name of company: Bepak plc
2. Name of scheme: Bepak 1996 Executive Share Option Scheme
3. Period of return: From 24 January 2006 to 25 July 2006

4. Number and class of shares(s) (amount of stock/debt security) not issued under scheme at the end of the last period:

132,578

5. Number of shares issued/allotted under scheme during period: NIL

6. Balance under scheme not yet issued/allotted at end of period: 132,578

7. Number and class of share(s) (amount of stock/debt securities) originally listed and the date of admission:

200,000 ordinary shares on 21 January 2000

Please confirm total number of shares in issue at the end of the period in order for us to update our records:

28,010,173

Contact for queries: Jenny Owen, Company Secretary

Address: Blackhill Drive, Featherstone Road, Wolverton Mill South, Milton Keynes, Bucks. MK12 5TS.

Name of person making return: Jenny Owen

Telephone: 01908 525211

ENDS

This information is provided by RNS
The company news service from the London Stock Exchange

investigate

a Financial Express and Inclusive Media partnership

Bespak PLC - Directorate Change

Bespak PLC
27 July 2006

Bespak plc

Executive Appointment

Bespak plc, a leader in devices for inhaled drug delivery and anaesthesia, today announces the appointment of Jonathan M. Glenn as Group Finance Director, effective 11 September 2006. Jon, aged 37, replaces Martin Hopcroft, who steps down from the Board today and will be leaving the Company on 8 September to pursue other opportunities.

From 1998 to 2005 Jon Glenn was Global Head of Finance of Celltech Group plc. Following the sale of Celltech to UCB, in March 2005 he became Chief Financial Officer of Akubio, a Cambridge-based, private equity owned, developer of instrumentation for the life sciences industry. At Akubio Jon's responsibilities have included Finance, Investor Relations, IT and Legal. He is a member of the Institute of Chartered Accountants in England and Wales.

Jon Glenn has advised that, in accordance with paragraph 9.6.13 (2) - (6) of the Listing Rules, he has no details to disclose.

Martin Hopcroft has been Group Finance Director of Bespak since November 2002. He was, previously, Chief Financial Officer of Kvaerner Oil & Gas and Group Finance Director of Darby Group plc.

On 12 July Bespak announced record financial results in the 52 weeks ended 29 April 2006. Sales grew 17% and operating profit increased 24%.

John Robinson, Bespak Chairman, said: 'I would like to thank Martin for his many contributions to Bespak over the past four years, during which time we have relied on his technical skills, commitment and good judgement.'

'Over the last year, Bespak has been transformed to focus on inhaled drug delivery and anaesthesia with significant opportunities for future growth in both the US and Europe. I am delighted that someone with Jon's ability is joining the Board at such an exciting time in Bespak's development. His experience and track record will be a great asset to the company'.

For further information, please contact:

Bespak plc
Mark Throdahl - Chief Executive

Tel: +44 (0) 1908 525240

Maitland
Brian Hudspith
Elizabeth Morley

Tel: +44 (0) 20 7379 5151

About Bespak plc

Bespak, a leader in devices for inhaled drug delivery and anaesthesia, develops delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings. Bespak's product range includes metered dose and dry powder inhalers, actuators, inflation valves, breathing circuits, disposable face masks and laryngeal tubes. The group, which has facilities in King's Lynn and Milton Keynes in the UK and Indianapolis, Indiana and Kent, Ohio, in the US, is quoted on the Official List of the London Stock Exchange (LSE: BPK). For more information, please visit www.bespak.com.

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bespak PLC - Holding(s) in Company

Bespak PLC
28 July 2006

NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Name of Company

Bespak plc

2. Name of shareholder having a major interest

Barclays plc and its subsidiaries

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18

As in 2 above

4. Name of each of the registered holder(s) and, if more than one holder, the number of shares held by each of them

Legal Entity	Holding	Percentage Held
Barclays Global Investors	1,224,660	4.3706
Woolwich Unit Trust Managers Ltd	73,187	0.2612
Gerrard Ltd	10,100	0.0360
Barclays Life Assurance Co Ltd	101,295	0.3615
Barclays Bank plc	132,175	0.4717
Barclays Private Bank Ltd	135,310	0.4829
Barclays Capital Securities Ltd	282,764	1.0091
Barclays Global Investors Ltd	817,982	2.9192
Barclays Funds Ltd	83,949	0.2996
Gerrard Ltd	4,832	0.0172
Group Holding	2,866,254	10.2290

Registered Holder	Holding
Bank of Ireland	20,622
Bank of Ireland	30,752
Bank of Ireland	13,233
Bank of Ireland Nominees Ltd	132,175
Bank of New York	13087
Bank of New York	41,188
Bank of New York	5,554
Barclays Capital Nominees Ltd	282,764
Chase Nominees Ltd	12,636
Chase Nominees Ltd	2,336
Chase Nominees Ltd	23,392
Chase Nominees Ltd	47,459
Chase Nominees Ltd	784,586
Chase Nominees Ltd	104,297
Chase Nominees Ltd	12,591
Chase Nominees Ltd	80,892
Chase Nominees Ltd	15,836
Chase Nominees Ltd	7,896
Chase Nominees Ltd	62,040
Citibank	48,297
HSBC	1,149
JP Morgan (BGI CUSTODY)	12,206
JP Morgan (BGI CUSTODY)	26,434
JP Morgan (BGI CUSTODY)	14,498
JP Morgan (BGI CUSTODY)	6,298
JP Morgan (BGI CUSTODY)	18,127
JP Morgan (BGI CUSTODY)	178,862
JP Morgan (BGI CUSTODY)	127,132
JP Morgan (BGI CUSTODY)	1,232
JP Morgan (BGI CUSTODY)	17,147
JP Morgan (BGI CUSTODY)	83,989

JP Morgan (BGI CUSTODY	3,629
Midland Bank (HSBC BANK PLC)	36,172
Northern Trust	42,394
Northern Trust	8,985
Northern Trust	57,801
Northern Trust	241,588
Northern Trust	79,104
RC Greig Nominees Limited	2,500
RC Greig Nominees Limited	500
RC Greig Nominees Limited a/cAK1	6,600
RC Greig Nominees Limited a/cBL1	1,500
RC Greig Nominees Limited a/c CML	1,500
RC Greig Nominees Limited GP1	2,332
STATE STREET	4,703
STATE STREET	12,969
ZEBAN NOMINEES LIMITED	135,310
Group Holding	2,866,254

5. Number of shares/amount of stock acquired

n/a

6. Percentage of issued class

n/a

7. Number of shares/amount of stock disposed

n/a

8. Percentage of issued class

n/a

9. Class of security

Ordinary GBP 0.10 shares

10. Date of transaction

18 July 2006

11. Date Company informed

27 July 2006

12. Total following this notification

10,2290

13. Total percentage holding of issued class following this notification

10.23%

14. Any additional information

Figures are based on shares in issue of 28,020,568

15. Name of contact and telephone number for queries

16. Name and signature of authorised company official responsible for making this notification

Jenny Owen

Company Secretary

01908 525211

Date of Notification: 27 July 2006

This information is provided by RNS
The company news service from the London Stock Exchange

investegate

a Financial Express and Incisive Media partnership

Bepak PLC - Disposal

Bepak PLC
03 August 2006

Withdrawal from the Consumer Dispensers Business

Bepak plc, a leader in devices for inhaled drug delivery and anaesthesia, today announces that it will withdraw from its loss-making Consumer Dispensers business segment, based in King's Lynn, Norfolk. Over the next five months, Bepak will execute an orderly shut-down of the business, efforts to sell it to qualified buyers having proved unsuccessful.

Last month Bepak reported sales in its financial year ending 29 April 2006 of £93.1m (up 17%) and profit before tax and special items of £13.5m (up 24%). Consumer Dispensers, which manufactures pumps for consumer household products, toiletries and fragrances, is the smallest of Bepak's three business segments and reported sales growth of 3% to £5.5m and an operating loss of £1.0m.

It is estimated that the closure of Consumer Dispensers will be broadly cash flow neutral, but that a non-recurring accounting charge of up to £3m will be taken by the end of this financial year, reflecting primarily severance costs and fixed asset impairment charges on customised manufacturing equipment and facilities. Bepak expects that, once implemented, the closure will produce on-going annual savings of at least £0.5m.

Bepak intends that, wherever possible, the 54 employees affected by the shut-down will be redeployed into its growing Inhaled Drug Delivery business. Bepak will work to assist customers in the phased transfer of the business to alternative suppliers.

Mark Throdahl, Bepak's Chief Executive, commented, 'Bepak has been transformed into a group focused on devices for inhaled drug delivery and anaesthesia, where we see significant growth opportunities. This closure will enhance group profitability and enable Bepak to focus on its declared growth market in medical devices.'

For further information, please contact:

Bepak plc
Mark Throdahl - Chief Executive
Paul Boughton - Corporate Development Director

Tel: +44 (0) 1908 525 240

Maitland
Elizabeth Morley

Tel: +44 (0) 207 379 5151

About Bepak plc

Bepak, a leader in devices for inhaled drug delivery and anaesthesia, develops delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings. Bepak's product range includes metered dose and dry powder inhalers, actuators, inflation valves, breathing circuits, disposable face masks and laryngeal tubes. The group, which has facilities in King's Lynn and Milton Keynes in the UK and Indianapolis, Indiana and Kent, Ohio, in the US, is quoted on the Official List of the London Stock Exchange (LSE: BPK). For more information, please visit www.bepak.com.

This information is provided by RNS
The company news service from the London Stock Exchange

The company news service from the London Stock Exchange
LS



■ Financial Express and Inclusive Media partnership

Bespak PLC - Director/PDMR Shareholding

Bespak PLC

04 August 2006

Notification of transactions of a director of Bespak plc and/or their Connected Persons

In fulfilment of my obligations under:

Disclosure Rule 3.1.2R and Section 324 (as extended by section 328) of the Companies Act 1985.

I notify you of the following:

1. Insert name of director:

Paul Boughton

2. If notification relates to a connected person insert name of connected person

Pauline Boughton (in respect of 50% of the purchase notified hereunder)

3. Indicate whether notification is in respect of the holding of the person referred to in 1 or 2 above or in respect of a non-beneficial interest

Notification is in respect of the person referred to in 1 above

4. Insert description of shares, debentures, or other financial instrument e.g. ordinary shares of 10p each in Bespak plc

Ordinary 10p shares

5. Insert number of shares, debentures, or other financial instruments acquired

Two thousand three hundred and seventy (2,370)

6. Insert nature of transaction e.g. purchased / sold

Purchased

7. Insert price per share or value of transaction

623p

8. Insert date of transaction

4th August 2006

9. Insert the percentage of total issued shares following the transaction held by the director

0.0512%

Jenny Owen
Company Secretary
Bespak plc

This information is provided by RNS

investegate

a Financial Express and Incisive Media partnership

Bespak PLC - Holding(s) in Company

Bespak PLC

11 August 2006

NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Name of Company

Bespak plc

2. Name of shareholder having a major interest

Barclays plc and its subsidiaries

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non beneficial interest or in the case of a an individual holder if it is a holding of that person's spouse or children under the age of 18

As in 2 above

4. Name of each of the registered holder(s)and, if more than one holder, the number of shares held by each of them

Legal Entity	Holding	Percentage Held
Gerrard Ltd	4,832	0.0172
Barclays Global Investors Ltd	1,377,495	4.9160
Barclays Private Bank Ltd	135,310	0.4829
Barclays Funds Ltd	83,949	0.2996
Gerrard Ltd	10,100	0.0360
Woolwich Unit Trust Managers Ltd	107,388	0.3832
Barclays Global Investors Ltd	899,180	3.2090
Barclays Life Assurance Co Ltd	101,295	0.3615
Barclays Bank plc	132,175	0.4717
Barclays Capital Securities Ltd	282,764	1.0091
Group Holding	3,134,488	11.1862

Registered Holder	Holding
Bank of Ireland	20,622
Bank of Ireland	30,752
Bank of Ireland	13,233
Bank of Ireland Nominees Ltd	132,175
Bank of New York	13,087
Bank of New York	41,188
Bank of New York	5,554
Barclays Capital Nominees Ltd	282,764
Chase Nominees Ltd	12,636
Chase Nominees Ltd	36,537
Chase Nominees Ltd	23,392
Chase Nominees Ltd	47,459
Chase Nominees Ltd	897,215
Chase Nominees Ltd	144,503
Chase Nominees Ltd	12,591
Chase Nominees Ltd	80,892
Chase Nominees Ltd	7,896
Chase Nominees Ltd	15,836
Chase Nominees Ltd	62,040
Citibank	89,590
HSBC	1,149
JP Morgan (BGI CUSTODY)	12,206
JP Morgan (BGI CUSTODY)	26,434
JP Morgan (BGI CUSTODY)	14,498
JP Morgan (BGI CUSTODY)	6,298
JP Morgan (BGI CUSTODY)	18,127
JP Morgan (BGI CUSTODY)	178,862
JP Morgan (BGI CUSTODY)	127,132
JP Morgan (BGI CUSTODY)	17,591
JP Morgan (BGI CUSTODY)	17,147

JP Morgan (BGI CUSTODY	83,989
JP Morgan (BGI CUSTODY	3,629
Midland Bank (HSBC BANK PLC)	36,172
Northern Trust	42,394
Northern Trust	8,985
Northern Trust	80,307
Northern Trust	247,331
Northern Trust	79,104
RC Greig Nominees Limited	500
RC Greig Nominees Limited	2,500
RC Greig Nominees Limited a/cAK1	6,600
RC Greig Nominees Limited a/cBL1	1,500
RC Greig Nominees Limited a/c CM1	1,500
RC Greig Nominees Limited GP1	2,332
STATE STREET	12,969
ZEBAN NOMINEES LIMITED	135,310
Group Holding	3,134,488

5. Number of shares/amount of stock acquired

n/a

6. Percentage of issued class

n/a

7. Number of shares/amount of stock disposed

n/a

8. Percentage of issued class

n/a

9. Class of security

Ordinary GBP 0.10 shares

10. Date of transaction

04 August 2006

11. Date Company informed

10 August 2006

12. Total following this notification

3,134,388

13. Total percentage holding of issued class following this notification

11.19%

14. Any additional information

Figures are based on shares in issue of 28,020,568

15. Name of contact and telephone number for queries

16. Name and signature of authorised company official responsible for making this notification

Jenny Owen
 Company Secretary
 01908 525211
 Date of Notification 11 August 2006

This information is provided by RNS
 The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bepak PLC - Director/PDMR Shareholding

Bepak PLC
16 August 2006

NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS

1. Name of the issuer

Bepak plc

2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or (ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii)

(iii)

3. Name of persons discharging managerial responsibilities/director

Mark Throdahl Director
Paul Boughton Director
Chris Hall PDMR
Joe Barry PDMR
Keyvan Djamarani PDMR
Jenny Owen Company Secretary

4. State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

N/A

5. Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest

In 3 above

6. Description of shares (including class), debentures or derivatives or financial instruments relating to shares

N/A

7. Name of Registered Shareholders and, if more than one, the number of shares held by each of them

N/A

8. State the nature of the transaction

N/A

9. Number of shares, debentures or financial instruments relating to shares acquired

N/A

10. Percentage of Issued Class acquired

N/A

11. Number of shares, debentures or financial instruments relating to shares disposed

N/A

12. Percentage of issued class disposed

N/A

13. Price per share or value of transaction

N/A

14. Date and Place of transaction

N/A

15. Total holding following notification and total percentage holding following notification

N/A

16. Date issues informed of transaction

N/A

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

17. Date of grant

8 August 2006

18. Period or date on which it can be exercised

8 August 2009 provided the applicable performance criteria have been satisfied.

19. Total amount paid (if any) for grant of option

NIL

20. Description of shares or debentures involved (class and number) Grant of Performance Shares and Share Appreciation Rights ('SARS') under the Bepak 2005 LTIP in respect of Ordinary 10p shares each as follows

	Performance Shares	SARS
Mark Throdahl	15,000	99,000
Paul Boughton	28,000	Nil
Chris Hall	6,500	19,500
Keyvan Djamrani	12,000	Nil
Joe Barry	10,000	Nil
Jenny Owen	6,000	Nil

21. Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

£6.20

22. Total number of shares or debentures over which options held following notification

Name	Share Options	Performance Shares	SARS
Mark Throdahl	462,000	39,000	171,000
Paul Boughton	Nil	43,000	Nil
Chris Hall	82,000	18,500	195,000
Keyvan Djamrani	16,500	23,000	Nil
Joe Barry	Nil	12,000	Nil
Jenny Owen	Nil	6,000	Nil

23. Any additional information

N/A

24. Name of contact and telephone number for queries

Jenny Owen
Tel 01908 525211

Name and signature of duly authorised officer of issuer responsible for aiming notification

Jenny Owen
Company Secretary

16th August 2006

END

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bespak PLC - Annual Information Update

Bespak PLC
18 August 2006

Bespak plc

Annual Information Update

In accordance with Prospectus Rule 5.2, the following information has been published or made available to the public in the 12 months up to and including 18 August 2006.

The following announcements have been made via RNS, a Regulatory Information Service.

Date of Announcement	Regulatory Headline
25 August 2005	Financial Calendar
8 September 2005	AGM statement
9 September 2005	Result of AGM
30 September 2005	Blocklisting Interim Review
4 October 2005	New Company Secretary
11 October 2005	Share Incentive Plan
14 October 2005	Exubera Update
24 October 2005	Block listing interim review
26 October 2005	Block listing interim review
8 November 2005	Share Incentive Plan
14 November 2005	Peter Fellner Appointment
14 November 2005	Trading Statement
2 December 2005	Additional Listing
6 December 2005	Posting of Circular
6 December 2005	Proposed Acquisition
8 December 2005	Director/PDMR Holding
22 December 2005	Result of EGM
23 December 2005	Acquisition and Blocklisting
4 January 2006	Notification of shares
4 January 2006	Notification of shares
4 January 2006	Notice of Results
6 January 2006	Holding(s) in Company
10 January 2006	Director/PDMR Holding
13 January 2006	Adoption of IFRS
18 January 2006	Interim Results
24 January 2006	Blocklisting Return
27 January 2006	Director/PDMR Holding
27 January 2006	Exubera Regulatory Approval
30 January 2006	Exubera Approval in US
6 February 2006	Director/PDMR Holding
9 March 2006	Company Secretary Change
14 March 2006	Director Share Purchase
27 March 2006	Director/PDMR Shareholding
30 March 2006	Block Listing Review
4 April 2006	Holding(s) in Company
19 April 2006	Holding(s) in Company
24 April 2006	Blocklisting Review
25 April 2006	Blocklisting Review
26 April 2006	Board Changes
26 April 2006	Director Share Purchase
2 May 2006	Director/PDMR Shareholding
2 May 2006	Blocklisting Review
10 May 2006	PDMR Shareholding
11 May 2006	Holding(s) in Company
12 May 2006	Director/PDMR Shareholding
22 May 2006	Holding(s) in Company
30 May 2006	Holding(s) in Company
2 June 2006	Directorate Change
20 June 2006	Facility Visit
28 June 2006	Holding(s) in Company
30 June 2006	Holding(s) in Company

12 July 2006	Final Results
13 July 2006	Director/PDMR Shareholding
14 July 2006	Holding(s) in Company
25 July 2006	Blocklisting Review
27 July 2006	Change of Director
28 July 2006	Holding(s) in Company
3 August 2006	Close of HPC Business
4 August 2006	Director/PDMR Shareholding
11 August 2006	Holding(s) in Company
16 August 2006	Director/PDMR Shareholding

In accordance with the provisions of Article 27.3 of the Prospectus Directive Regulation, we confirm that to the best of our knowledge, information relating to 'Holdings in Company', 'Directors' Shareholdings' and 'Director/PDMR Shareholdings' is up to date at the date of this announcement but it is acknowledged that such disclosures may, at any time, become out of date, due to changing circumstances.

Details of all regulatory announcements for Bepak plc can be found on the prices page of the London Stock Exchange website at www.londonstockexchange.com and any related documents are available at the UKLA's Document Viewing Facility, Financial Services Authority, 25 The Colonnade, Canary Wharf, London E14 5HS.

The Company has also made the following filings with Companies House:

Date of Filing	Document filed
9 September 2005	Resignation of Director
15 September 2005	Return of Allotment of Shares
15 September 2005	Return of Allotment of Shares
15 September 2005	Return of Allotment of Shares
15 September 2005	Return of Allotment of Shares
23 September 2005	Return of Allotment of Shares
26 September 2005	Annual Return
30 September 2005	Appointment of Company Secretary
30 September 2005	Resignation of Company Secretary
1 November 2005	Return of Allotment of Shares
4 November 2005	Return of Allotment of Shares
17 November 2005	Appointment of Director
14 December 2005	Return of Allotment of Shares
9 January 2006	Return of Allotment of Shares
27 January 2006	Return of Allotment of Shares
28 January 2006	Return of Allotment of Shares
30 January 2006	Appointment of Director
6 February 2006	Return of Allotment of Shares
8 March 2006	Return of Allotment of Shares
21 March 2006	Appointment of Company Secretary
21 March 2006	Resignation of Company Secretary
11 May 2006	Return of Allotment of Shares
14 June 2006	Appointment of Director
16 June 2006	Resignation of Director
16 June 2006	Appointment of Director
11 August 2006	Resignation of Director

Copies of these documents can be obtained from Companies House or through Companies House Direct at www.direct.companieshouse.gov.uk

Further information is available regarding the Company and its activities on its website at www.bepak.com.

The Bepak plc Annual Report 2005 and the AGM circular was filed with the UKLA Document Viewing Facility on 15 August 2005 and can also be found on the Company's website or on application to the Company Secretary. The Bepak plc Annual Report 2006 and AGM Circular will be posted on or about 25th August 2006 and will also be posted on the Company's website and will be available from the Company Secretary upon application.

Jenny Owen
Company Secretary
01908 525211

18 August 2006

This information is provided by RNS

The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bespak PLC - Director/PDMR Shareholding

Bespak PLC

21 August 2006

NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS

This form is intended for use by an issuer to make a RIS notification required by DR 3.1.4R(1).

- (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.
- (2) An issuer making a notification in respect of a derivative relating to the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.
- (3) An issuer making a notification in respect of options granted to a director /person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.
- (4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

Please complete all relevant boxes in block capital letters.

1. Name of the issuer

BESPAK PLC

2. State whether the notification relates to

- (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or
- (ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or
- (iii) both (i) and (ii)
- (iii) both

3. Name of person discharging managerial responsibilities/director

Joe Barry (PDMR)

4. State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

N/A

5. Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest

THE NOTIFICATION IS IN RESPECT OF HOLDINGS OF THE PERSON REFERRED TO IN 3 ABOVE

6. Description of shares (including class), debentures or derivatives or financial instruments relating to shares

ORDINARY SHARES OF 10p EACH

7. Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

Joe Barry

8. State the nature of the transaction

PURCHASE OF ORDINARY SHARES

9. Number of shares, debentures or financial instruments relating to shares acquired
1,500
10. Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)
0.01%
11. Number of shares, debentures or financial instruments relating to shares disposed
N/A
12. Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)
N/A
13. Price per share or value of transaction
£6.10 PER SHARE
14. Date and place of transaction
18 August 2006
LONDON
15. Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)
3,300 ORDINARY SHARES (0.011%)
16. Date issuer informed of transaction
21 August 2006
- If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes
17. Date of grant
N/A
18. Period during which or date on which it can be exercised
N/A
19. Total amount paid (if any) for grant of the option
N/A
20. Description of shares or debentures involved (class and number)
N/A
21. Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise
N/A
22. Total number of shares or debentures over which options held following notification
N/A
23. Any additional information
NONE
24. Name of contact and telephone number for queries
COMPANY SECRETARY

Name and signature of duly authorised officer of issuer responsible for making notification

JENNY OWEN

Date of notification

21 August 2006

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bespak PLC - Holding(s) in Company

Bespak PLC

22 August 2006

NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Name of Company

Bespak plc

2. Name of shareholder having a major interest

Barclays plc and its subsidiaries

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non beneficial interest or in the case of a an individual holder if it is a holding of that person's spouse or children under the age of 18

As in 2 above

4. Name of each of the registered holder(s) and, if more than one holder, the number of shares held by each of them

Legal Entity	Holding	Percentage Held
Barclays Capital Securities Ltd	282,764	1.0091
Barclays Global Investors Ltd	1,041,061	3.7153
Barclays Global Investors Ltd	2,093,676	7.4719
Barclays Private Bank Ltd	130,310	0.4650

Gerrard Ltd	4,832	0.0172
Barclays Funds Ltd	78,508	0.2801
Barclays Life Assurance Co Ltd	122,283	0.4611
Woolwich Unit Trust Managers Ltd	122,283	0.4364
Gerrard Ltd	10,100	0.0360
Barclays Bank plc	132,175	0.4717
Group Holding	4,024,933	14.3641

Registered Holder	Holding
Bank of Ireland	22,258
Bank of Ireland	41,796
Bank of Ireland	13,233
Bank of Ireland Nominees Ltd	132,175
Bank of New York	16,750
Bank of New York	50,559
Bank of New York	5,554
Barclays Capital Nominees Ltd	282,764
Chase Nominees Ltd	12,636
Chase Nominees Ltd	38,287
Chase Nominees Ltd	23,392
Chase Nominees Ltd	47,459
Chase Nominees Ltd	1,613,396
Chase Nominees Ltd	144,503
Chase Nominees Ltd	12,591
Chase Nominees Ltd	80,892
Chase Nominees Ltd	19,280
Chase Nominees Ltd	7,896
Chase Nominees Ltd	74,058
Citibank	94,939
HSBC	1,149
JP Morgan (BGI CUSTODY)	12,206
JP Morgan (BGI CUSTODY)	42,031
JP Morgan (BGI CUSTODY)	14,498
JP Morgan (BGI CUSTODY)	6,298
JP Morgan (BGI CUSTODY)	27,015
JP Morgan (BGI CUSTODY)	178,862
JP Morgan (BGI CUSTODY)	127,132
JP Morgan (BGI CUSTODY)	5,441
JP Morgan (BGI CUSTODY)	17,591
JP Morgan (BGI CUSTODY)	17,147

JP Morgan (BGI CUSTODY)	78,508
JP Morgan (BGI CUSTODY)	3,629
JP Morgan (BGI CUSTODY)	6,597
Midland Bank (HSBC BANK PLC)	63,116
Northern Trust	58,730
Northern Trust	8,985
Northern Trust	80,307
Northern Trust	247,331
Northern Trust	120,586
RC Greig Nominees Limited	500
RC Greig Nominees Limited	2,500
RC Greig Nominees Limited a/cAK1	6,600
RC Greig Nominees Limited a/cBL1	1,500
RC Greig Nominees Limited a/c CM1	1,500
RC Greig Nominees Limited GP1	2,332
STATE STREET	12,969
ZEBAN NOMINEES LIMITED	130,310
Group Holding	4,024,933

5. Number of shares/amount of stock acquired

n/a

6. Percentage of issued class

n/a

7. Number of shares/amount of stock disposed

n/a

8. Percentage of issued class

n/a

9. Class of security

Ordinary GBP 0.10 shares

10. Date of transaction

16 August 2006

11. Date Company informed

21st August 2006

12. Total following this notification

4,024,933

13. Total percentage holding of issued class following this notification

14.36%

14. Any additional information

Figures are based on shares in issue of 28,021,018

15. Name of contact and telephone number for queries

16. Name and signature of authorised company official responsible for making this notification

Jenny Owen
Company Secretary
01908 525211

Date of Notification 22 August 2006

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bespak PLC - Holding(s) in Company

Bespak PLC
23 August 2006

NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Name of Company

Bespak plc

2. Name of shareholder having a major interest

Barclays plc and its subsidiaries

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non beneficial interest or in the case of a an individual holder if it is a holding of that person's spouse or children under the age of 18

As in 2 above

4. Name of each of the registered holder(s) and, if more than one holder, the number of shares held by each of them

Legal Entity	Holding	Percentage Held
Barclays Capital Securities Ltd	282,764	1.0091
Gerrard Ltd	10,100	0.0360
Barclays Global Investors Ltd	1,211,028	4.3218
Barclays Funds Ltd	78,508	0.2802
Gerrard Ltd	4,832	0.0172
Barclays Bank plc	132,175	0.4717
Barclays Private Bank Ltd	130,310	0.4650
Woolwich Unit Trust Managers Ltd	128,735	0.4594
Barclays Global Investors Ltd	2,393,268	8.5409
Barclays Life Assurance Co Ltd	139,971	0.4988
Group Holding	4,511,691	16.1011

Registered Holder	Holding
Bank of Ireland	24,258
Bank of Ireland	46,625
Bank of Ireland	13,233
Bank of Ireland Nominees Ltd	132,175
Bank of New York	16,750
Bank of New York	50,559
Bank of New York	5,554
Barclays Capital Nominees Ltd	282,764
Chase Nominees Ltd	12,636
Chase Nominees Ltd	36,537
Chase Nominees Ltd	44,739
Chase Nominees Ltd	47,459
Chase Nominees Ltd	1,912,988
Chase Nominees Ltd	144,503
Chase Nominees Ltd	12,591
Chase Nominees Ltd	80,892
Chase Nominees Ltd	7,896
Chase Nominees Ltd	19,280
Chase Nominees Ltd	78,632
Citibank	135,253
HSBC	1,149
JP Morgan (BGI CUSTODY)	12,206
JP Morgan (BGI CUSTODY)	14,498
JP Morgan (BGI CUSTODY)	48,870
JP Morgan (BGI CUSTODY)	6,298
JP Morgan (BGI CUSTODY)	30,923
JP Morgan (BGI CUSTODY)	178,862
JP Morgan (BGI CUSTODY)	127,132
JP Morgan (BGI CUSTODY)	74,994

JP Morgan (BGI CUSTODY)	17,591
JP Morgan (BGI CUSTODY)	17,147
JP Morgan (BGI CUSTODY)	78,508
JP Morgan (BGI CUSTODY)	3,629
JP Morgan (BGI CUSTODY)	6,597
Midland Bank (HSBC BANK PLC)	72,441
Northern Trust	66,014
Northern Trust	8,985
Northern Trust	101,686
Northern Trust	247,331
Northern Trust	133,295
RC Greig Nominees Limited	500
RC Greig Nominees Limited	2,500
RC Greig Nominees Limited a/cAK1	6,600
RC Greig Nominees Limited a/cBL1	1,500
RC Greig Nominees Limited a/c CML	1,500
RC Greig Nominees Limited GP1	2,332
STATE STREET	12,969
ZEBAN NOMINEES LIMITED	130,310
Group Holding	4,511,691

5. Number of shares/amount of stock acquired

n/a

6. Percentage of issued class

n/a

7. Number of shares/amount of stock disposed

n/a

8. Percentage of issued class

n/a

9. Class of security

Ordinary GBP 0.10 shares

10. Date of transaction

17 August 2006

11. Date Company informed

22nd August 2006

12. Total following this notification

4,511,691

13. Total percentage holding of issued class following this notification

16.1011%

14. Any additional information

Figures are based on shares in issue of 28,021,018

15. Name of contact and telephone number for queries

16. Name and signature of authorised company official responsible for making this notification

Jenny Owen
Company Secretary
01908 525211

Date of Notification 23 August 2006

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bespak PLC - Annual Report and Accounts

Bespak PLC
29 August 2006

ANNUAL REPORT AND ACCOUNTS

Bespak plc issued its 2006 Annual Report and Accounts on 29 August 2006. A copy of the document together with the Company's Notice of Annual General Meeting, has been submitted to the UK Listing Authority, and is available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at:

The Financial Services Authority
25 The North Colonnade
Canary Wharf
London
E14 5HS

Tel. +44 (0)20 7066 1000

This information is provided by RNS
The company news service from the London Stock Exchange

investegate

a Financial Express and Incisive Media partnership

Bespak PLC - Holding(s) in Company

Bespak PLC
30 August 2006

NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Name of Company

Bespak plc

2. Name of shareholder having a major interest

Barclays plc and its subsidiaries

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non beneficial interest or in the case of a an individual holder if it is a holding of that person's spouse or children under the age of 18

As in 2 above

4. Name of each of the registered holder(s) and, if more than one holder, the number of shares held by each of them

Legal Entity	Holding	Percentage Held
Barclays Bank plc	1,32,175	0.4717
Barclays Capital Securities Ltd	282,764	1.0091
Barclays Funds Limited	78,508	0.2802
Woolwich Unit Trust Managers Ltd	134,885	0.4814
Gerrard Ltd	4,832	0.0172
Barclays Life Assurance Co Ltd	149,368	0.5331
Barclays Global Investors Ltd	2,763,811	9.8633
Barclays Private Bank Ltd	130,310	0.4651
Barclays Global Investors Ltd	1,229,364	4.3873
Gerrard Ltd	10,100	0.0360
Group Holding	4,916,117	17.544

Registered Holder	Holding
Bank of Ireland	24,258
Bank of Ireland	51,171
Bank of Ireland	13,233
Bank of Ireland Nominees Ltd	132,175
Bank of New York	20,126
Bank of New York	50,559
Bank of New York	5,554
Barclays Capital Nominees Ltd	282,764
Chase Nominees Ltd	12,636
Chase Nominees Ltd	36,537
Chase Nominees Ltd	50,889
Chase Nominees Ltd	47,459
Chase Nominees Ltd	2,283,531
Chase Nominees Ltd	144,503
Chase Nominees Ltd	12,591
Chase Nominees Ltd	80,892
Chase Nominees Ltd	7,896
Chase Nominees Ltd	19,280
Chase Nominees Ltd	78,632
Citibank	135,253
HSBC	1,149
JP Morgan (BGI CUSTODY)	12,206
JP Morgan (BGI CUSTODY)	54,904
JP Morgan (BGI CUSTODY)	14,498
JP Morgan (BGI CUSTODY)	6,298
JP Morgan (BGI CUSTODY)	34,286

JP Morgan (BGI CUSTODY)	178,862
JP Morgan (BGI CUSTODY)	127,132
JP Morgan (BGI CUSTODY)	74,994
JP Morgan (BGI CUSTODY)	17,591
JP Morgan (BGI CUSTODY)	17,147
JP Morgan (BGI CUSTODY)	78,508
JP Morgan (BGI CUSTODY)	3,629
Midland Bank (HSBC BANK PLC)	82,625
Northern Trust	66,014
Northern Trust	8,985
Northern Trust	101,686
Northern Trust	247,331
Northern Trust	140,122
RC Greig Nominees Limited	2,500
RC Greig Nominees Limited	500
RC Greig Nominees Limited a/cAK1	6,600
RC Greig Nominees Limited a/cBL1	1,500
RC Greig Nominees Limited a/c CM1	1,500
RC Greig Nominees Limited GP1	2,332
STATE STREET	12,969
ZEBAN NOMINEES LIMITED	130,310,310
Group Holding	4,916,117

5. Number of shares/amount of stock acquired

n/a

6. Percentage of issued class

n/a

7. Number of shares/amount of stock disposed

n/a

8. percentage of issued class

n/a

9. Class of security

Ordinary GBP 0.10 shares

10. Date of transaction

23 August

11. Date Company informed

29 August 2006

12. Total following this notification

4,916,117

13. Total percentage holding of issued class following this notification

17.544%

14. Any additional information

Figures are based on shares in issue of 28,021,018

15. Name of contact and telephone number for queries

16. Name and signature of authorised company official responsible for making this notification

Jenny Owen
Company Secretary
01908 525211

Date of Notification 30 August 2006

This information is provided by RNS
The company news service from the London Stock Exchange

investegate

a Financial Express and Inclusive Media partnership

Bespak PLC - Annual Report

Bespak PLC
12 September 2006

Dear Shareholder,

Information supplemental to the Bespak plc 2006 Annual Report and Accounts.

You will recently have received our 2006 Annual Report and Accounts. The information contained in this letter was not included in the Remuneration Report. This information adds to and should be treated as part of that Report and is effective as at 11th July 2006, the date of that Report. It does not deal with any events after that date.

We have added below a copy of a report from the Company's auditors in respect of this supplemental information.

By order of the Board
Jennifer M Owen
Company Secretary
For and on behalf of Bespak plc
7 September 2006

Directors' Benefits

Mark Throdahl receives a pension allowance which is paid by way of additional salary (2005: £81,000). The Company pays contributions to a defined contribution plan in respect of Mr Hopcroft (2005: £32,000).

The Company provides accommodation in the UK for Mr Throdahl in accordance with the terms of his service contract. This represents a taxable benefit and so is included in the figure for other benefits. Mr Throdahl contributes a proportion of the annual rental costs.

Mr Robinson's services are provided via a service company to which the Company pays fees.

Compensation for past directors

The Company provides a pension to the widow of an ex-director of £26,000 per annum in accordance with the terms of the former director's service arrangements. This is an unfunded pension paid out of annual profits.

Directors' share options

Name	Option Type	Options as at 30 April 2005	Granted during the year	Lapsed during the year	Options as at 29 April 2006	Exercise price	De exer
M C							
Throdahl	1996 ESOS	144,859	-	-	144,859	£5.835	Ju
	1996 CSOS	5,141	-	-	5,141	£5.835	Ju
	2002 ESOS	70,000	-	-	70,000	£4.43	Se
	2002 ESOS	35,000	-	-	35,000	£4.43	Se
	2002 ESOS	70,000	-	-	70,000	£4.125	Se
	2002 ESOS	35,000	-	-	35,000	£4.125	Se
	2002 ESOS	68,000	-	-	68,000	£5.09	Ju
	2002 ESOS	34,000	-	-	34,000	£5.09	Ju
	2005 LTIP	-	24,000	-	24,000	-	F
			performance shares				
	2005 LTIP	-	72,000 SARs	-	72,000	£6.14	F
M P							
Hopcroft	2002 ESOS	33,000	-	-	33,000	£2.975	I
	2002 ESOS	17,000	-	-	17,000	£2.975	I
	2002 ESOS	48,000	-	-	48,000	£4.125	S
	2002 ESOS	24,000	-	-	24,000	£4.125	S

SAYE	2,900	-	-	2,900	£3.18	
2002 ESOS	39,000	-	-	39,000	£5.09	J
2002 ESOS	19,500	-	-	19,500	£5.09	J
2005 LTIP	-	27,000	-	27,000	-	
		performance				
		shares				
	-----	-----	-----	-----		
	645,400	123,000	-	768,400		

* Performance shares will be transferred automatically to the Director in February 2009, if certain performance criteria have been met. The Director does not choose to exercise the right.

- The closing price of the shares at 29 April 2006 was 575.5 pence (30 April 2005: 517.5 pence). The lowest and highest middle market prices during the year were 480 pence and 662 pence respectively.
- SAYE = Save As You Earn employee share option scheme. These options are not subject to performance conditions as this is an all-employee share scheme governed by specific tax legislation.
- 1996 ESOS & CSOS = 1996 Executive and Company Share Option Scheme as described in the section on Executive Directors' Remuneration.
- 2002 ESOS = 2002 Executive Share Option Scheme as described in the section on Executive Directors' Remuneration.
- 2005 LTIP & Bepak 2005 Long-Term Incentive Plan as described in the section on Executive Directors' Remuneration.

At 29 April 2006, the Company's share ownership trust held no ordinary shares in the Company (30 April 2005: 3,741) for the purposes of satisfying obligations under share option plans for the benefit of the Group's employees.

The Remuneration Report was approved by the Board and signed on its behalf by:
George Meredith
Chairman of the Remuneration Committee
11 July 2006

Independent auditors' report to the members of Bepak plc

We have considered whether the information given in the revised Remuneration Report is consistent with the financial statements for the year ended 29 April 2006. The revised Remuneration Report comprises the above supplementary information and the original Remuneration Report which was approved by the directors on 11 July 2006. The revised Remuneration Report replaces the original Remuneration Report as from 7 September 2006 (the date on which the supplementary information is approved and signed).

As explained in the above supplementary information the Remuneration Report has been revised as at 11 July 2006, the date on which the directors approved the original financial statements and not as at 7 September 2006, the date on which the revised Remuneration Report was approved. Accordingly the revised Remuneration Report does not deal with events between those dates.

As at 11 July 2006 in our opinion the information given in the revised report is consistent with the annual financial statements for the year ended 29 April 2006.

PricewaterhouseCoopers LLP
Chartered Accountants and Registered Auditors, Cambridge
7 September 2006

This information is provided by RNS
The company news service from the London Stock Exchange

News Release

31 August 2006

Directorate Change

Bespak plc (LSE:BPK), a leader in speciality medical devices, is pleased to announce the appointment of George Kennedy, to the Board as a non-executive director. George will also become a member of the audit committee.

George, 66, is currently Chairman of E2v plc, Deputy Chairman of Vernalis plc, senior Independent Director of Isotron plc, deputy Chairman of Spacelabs plc and Chairman of Eschmann Limited.

He is a former Chairman of Smiths Industries Medical Group and past Chair of the ABHI. He is currently President of the ABHI. He was awarded the CBE in 1997 for services to Exports and to the Healthcare Industry.

In accordance with Listing Rule 9.6.15, it is confirmed that there are no details to be disclosed pursuant to Listing Rule 9.6.13.

Bespak also announces today the resignation of Jack Cashman and George Meredith as non-executive directors with effect from the close of the Company's Annual General Meeting to be held on 28th September.

John Robinson, Bespak's Chairman commented, "I am delighted to welcome George Kennedy to the Board. His considerable experience of the healthcare industry will be of great benefit to Bespak. I would also like to thank Jack Cashman and George Meredith, who resign due to their other commitments, for their invaluable contributions to the Board over a number of years."

For further information please contact:

Bespak

Mark Throdahl, Chief Executive

Tel: +44 (0)1908 552600

Maitland

Brian Hudspith or Liz Morley

Tel: +44 (0)20 7379 5151

About Bespak plc

Bespak, a leader in devices for inhaled drug delivery and anaesthesia, develops delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings. Bespak's product range includes metered dose and dry powder inhalers, actuators, inflation valves, breathing circuits, disposable face masks and laryngeal tubes. The group, which has facilities in King's Lynn and Milton Keynes in the UK and Indianapolis, Indiana and Kent, Ohio, in the US, is quoted on the Official List of the London Stock Exchange (LSE: BPK). For more information, please visit www.bespak.com.



a Financial Express and Incisive Media partnership

Bepak PLC - Director/PDMR Shareholding

Bepak PLC
08 September 2006

NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS

This form is intended for use by an issuer to make a RIS notification required by DR 3.1.4R(1).

- (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.
- (2) An issuer making a notification in respect of a derivative relating to the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.
- (3) An issuer making a notification in respect of options granted to a director /person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.
- (4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

Please complete all relevant boxes in block capital letters.

1. Name of the issuer

BESPAK PLC

2. State whether the notification relates to:

- (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or
- (ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or
- (iii) both (i) and (ii)

BOTH

3. Name of person discharging managerial responsibilities/director

JENNIFER OWEN(PDMR)

4. State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

N/A

5. Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest

THE NOTIFICATION IS IN RESPECT OF HOLDINGS OF THE PERSON REFERRED TO IN 3 ABOVE

6. Description of shares (including class), debentures or derivatives or financial instruments relating to shares

ORDINARY SHARES OF 10p EACH

7. Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

JENNIFER OWEN

8. State the nature of the transaction

PURCHASE OF ORDINARY SHARES

9. Number of shares, debentures or financial instruments relating to shares acquired
6,265
10. Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)
0.0223%
11. Number of shares, debentures or financial instruments relating to shares disposed
N/A
12. Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)
N/A
13. Price per share or value of transaction
£6.33 PER SHARE
14. Date and place of transaction
08 SEPTEMBER 2006
LONDON
15. Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)
6,265 ORDINARY SHARES (0.223%)
16. Date issuer informed of transaction
08 SEPTEMBER 2006
- If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes
17. Date of grant
N/A
18. Period during which or date on which it can be exercised
N/A
19. Total amount paid (if any) for grant of the option
N/A
20. Description of shares or debentures involved (class and number)
N/A
21. Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise
N/A
22. Total number of shares or debentures over which options held following notification
N/A
23. Any additional information
NONE
24. Name of contact and telephone number for queries
COMPANY SECRETARY

Name and signature of duly authorised officer of issuer responsible for making

notification

JENNY OWEN

Date of notification

08 SEPTEMBER 2006

This information is provided by RNS
The company news service from the London Stock Exchange

investegate

a Financial Express and Incisive Media partnership

Bepak PLC - Blocklisting

Bepak PLC
29 September 2006

SCHEDULE 5

BLOCKLISTING SIX MONTHLY RETURN

1. Name of company: Bepak plc
2. Name of scheme: Bepak 1996 Savings Related Share Option Scheme
3. Period of return: From 30 March 2006 to 30 September 2006
4. Number and class of shares(s) (amount of stock/debt security) not issued under scheme at the end of the last period: 400,000
5. Number of shares issued/allotted under scheme during period: NIL
6. Balance under scheme not yet issued/allotted at end of period: 400,000
7. Number and class of share(s) (amount of stock/debt securities) originally listed and the date of admission: 400,000 Ordinary on 22 March 2000

Please confirm total number of shares in issue at the end of the period in order for us to update our records 28,021,018.

Contact for queries: Jenny Owen
Blackhill Drive,
Featherstone Road,
Wolverton Mill South,
Milton Keynes,
Bucks. MK12 5TS

Name of person making return:
Jenny Owen
Telephone: 01908 525240

For more information on the Bepak Group please visit our Website at
www.Bepak.com

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bepak PLC - Result of AGM

Bepak PLC
28 September 2006

Bepak plc Result of Annual General Meeting

At today's Annual General Meeting of Bepak plc, a leader in medical devices for inhaled drug delivery and anaesthesia, all resolutions were duly approved.

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bepak PLC - AGM Statement

Bepak PLC
28 September 2006

Bepak plc Annual General Meeting

Bepak plc, a leader in medical devices for inhaled drug delivery and anaesthesia will have its AGM today. John Robinson, Chairman, will say:

'Last year was excellent for Bepak. Revenues increased 17% and operating profit before special items increased 34%. Our core Inhaled Drug Delivery businesses exceeded expectations, production began on the inhaler for Exubera(R), the world's first inhaled insulin, and King Systems was acquired.

'In the current financial year, which began 30 April 2006, trading has been strong across all Bepak's businesses, and King Systems, acquired in December 2005, has been successfully integrated. The withdrawal from the Consumer Dispensers business, announced in August, is proceeding as planned.'

'I am also pleased to welcome Jon Glenn to the Board as Finance Director. Jon joined the Group at the beginning of this month. Bepak now has a strong management team to take the business forward.'

For further information, please contact:

Bepak plc
Mark Throdahl - Chief Executive
Jon Glenn - Finance Director

Tel: +44 (0) 1908 525 240

Maitland
Brian Hudspith Liz Morley

Tel: +44 (0) 207 379 5151

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Enclave Media partnership

Bespak PLC - Director/PDMR Shareholding

Bespak PLC
02 October 2006

NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS

1. Name of the issuer

Bespak plc

2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or (ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii)

(iii)

3. Name of persons discharging managerial responsibilities/director

Jonathan Glenn

4. State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

N/A

5. Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest

In 3 above

6. Description of shares (including class), debentures or derivatives or financial instruments relating to shares

N/A

7. Name of Registered Shareholders and, if more than one, the number of shares held by each of them

N/A

8. State the nature of the transaction

N/A

9. Number of shares, debentures or financial instruments relating to shares acquired

N/A

10. Percentage of Issued Class acquired

N/A

11. Number of shares, debentures or financial instruments relating to shares disposed

N/A

12. Percentage of issued class disposed

N/A

13. Price per share or value of transaction

N/A

14. Date and Place of transaction

N/A

15. Total holding following notification and total percentage holding following notification

N/A

16. Date issues informed of transaction

N/A

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

17. Date of grant

29 September 2006

18. Period or date on which it can be exercised

29 September 2009 provided the applicable performance criteria have been satisfied.

19. Total amount paid (if any) for grant of option

Nil

Description of shares or debentures involved (class and number) Grant of 26,000 Performance Shares

20. Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

614.5p

21. Total number of shares or debentures over which options held following notification

Nil

22. Any additional information

N/A

23. Name of contact and telephone number for queries

Jenny Owen tel 01908 525211

Name and signature of duly authorised officer of issuer responsible for aiming notification

Jenny Owen
Company Secretary

1st October 2006
END

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bepak PLC - Director/PDMR Shareholding

Bepak PLC
20 October 2006

NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS

1. Name of the issuer

Bepak plc

2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or (ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii)

(iii)

3. Name of persons discharging managerial responsibilities/director

George Kennedy - director

4. State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

N/A

5. Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest

In 3 above

6. Description of shares (including class), debentures or derivatives or financial instruments relating to shares

10p ordinary shares

7. Name of Registered Shareholders and, if more than one, the number of shares held by each of them

George Kennedy

8. State the nature of the transaction

Share Purchase

9. Number of shares, debentures or financial instruments relating to shares acquired

Two thousand

10. Percentage of Issued Class acquired

0.007 per cent

11. Number of shares, debentures or financial instruments relating to shares disposed

N/A

12. Percentage of issued class disposed

N/A

13. Price per share or value of transaction

£6.1625

14. Date and Place of transaction

London 18 October 2006

15. Total holding following notification and total percentage holding following notification

2,000 ordinary 10p shares 0.007 per cent

16. Date issues informed of transaction

20th October 2006

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

17. Date of grant

N/A

18. Period or date on which it can be exercised

N/A

19. Total amount paid (if any) for grant of option

N/A

Description of shares or debentures involved (class and number) Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

N/A

20. Total number of shares or debentures over which options held following notification

Nil

21. Any additional information

N/A

22. Name of contact and telephone number for queries

Jenny Owen
Tel 01908 525211

Name and signature of duly authorised officer of issuer responsible for aiming notification

Jenny Owen
Company Secretary

20th October 2006

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Incisive Media partnership

Bepak PLC - Blocklisting

Bepak PLC
23 October 2006

SCHEDULE 5

BLOCKLISTING SIX MONTHLY RETURN

1. Name of company: Bepak plc
2. Name of scheme: Bepak 1996 Savings Related Share Option Scheme
3. Period of return: From 23 April 2006 to 22 October 2006
4. Number and class of shares(s) (amount of stock/debt security) not issued under scheme at the end of the last period: 17,272
5. Number of shares issued/allotted under scheme during period: 636
6. Balance under scheme not yet issued/allotted at end of period: 16,636
7. Number and class of share(s) (amount of stock/debt securities) originally listed and the date of admission: 50,000 Ordinary shares on 16 April 1997

Please confirm total number of shares in issue at the end of the period in order for us to update our records: 28,024,704

Contact for queries: Jenny Owen

Address: Blackhill Drive
Featherstone Road
Wolverton Mill South
Milton Keynes
Bucks. MK12 5TS

Name of person making return: Jenny Owen
Company Secretary

Telephone: 01908 525211

For more information on the Bepak Group please visit our Website at
<http://www.bepak.com/>

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bepak PLC - Blocklisting

Bepak PLC
25 October 2006

SCHEDULE 5

BLOCKLISTING SIX MONTHLY RETURN

1. Name of company: Bepak plc
2. Name of scheme: Bepak 1996 Company Share Option Scheme
3. Period of return: From 26 April 2006 to 25 October 2006
4. Number and class of shares(s) (amount of stock/debt security) not issued under scheme at the end of the last period: 11,141
5. Number of shares issued/allotted under scheme during period: Nil
6. Balance under scheme not yet issued/allotted at end of period: 11,141
7. Number and class of share(s) (amount of stock/debt securities) originally listed and the date of admission: 50,000 Ordinary shares on 25 April 1997

Please confirm total number of shares in issue at the end of the period in order for us to update our records: 28,024,704

Contact for queries: Jenny Owen

Address: Blackhill Drive
Featherstone Road
Wolverton Mill South
Milton Keynes
Bucks. MK12 5TS

Name of person making return: Jenny Owen, Company Secretary
Telephone: 01908 525211

For more information on the Bepak Group please visit our Website at
www.Bepak.com

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bepak PLC - Holding(s) in Company

Bepak PLC
06 November 2006

NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Name of Company

Bepak plc

2. Name of shareholder having a major interest

Barclays plc and its subsidiaries

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non beneficial interest or in the case of a an individual holder if it is a holding of that person's spouse or children under the age of 18

As in 2 above

4. Name of each of the registered holder(s)and, if more than one holder, the number of shares held by each of them

Legal Entity	Holding	Percentage Held
Barclays Global Investors	2,632,369	9.3930
Woolwich Unit Trust Managers Ltd	109,578	0.3910
Gerrard Ltd	8,500	0.0303
Barclays Life Assurance Co Ltd	169,387	0.6043
Barclays Bank plc	97,156	0.3467
Barclays Private Bank Ltd	130,310	0.4650
Barclays Capital Securities Ltd	282,764	1.0090
Barclays Global Investors Ltd	1,244,234	4.4393
Barclays Funds Ltd	78,508	0.2801
Gerrard Ltd	4,080	0.0146
Group Holding	4,756,886	16.9633

Registered Holder	Holding
Bank of Ireland	24,258
Bank of Ireland	51,171
Bank of Ireland	13,233
Bank of Ireland Nominees Limited	97,156
Bank of New York	20,126
Bank of New York	50,559
Bank of New York	5,554
Barclays Capital Nominees Ltd	282,764
Chase Nominees Ltd	14,263
Chase Nominees Ltd	36,537
Chase Nominees Ltd	25,582
Chase Nominees Ltd	47,459
Chase Nominees Ltd	2,173,387
Chase Nominees Ltd	144,503
Chase Nominees Ltd	11,699
Chase Nominees Ltd	100,000
Chase Nominees Ltd	27,176
Chase Nominees Ltd	5,288
Chase Nominees Ltd	78,632
Citibank	135,253
HSBC	1,149
JP Morgan (BGI CUSTODY)	32,225
JP Morgan (BGI CUSTODY)	69,402
JP Morgan (BGI CUSTODY)	6,298
JP Morgan (BGI CUSTODY)	34,286
JP Morgan (BGI CUSTODY)	151,437
JP Morgan (BGI CUSTODY)	127,132
JP Morgan (BGI CUSTODY)	74,994

JP Morgan (BGI CUSTODY	17,591
JP Morgan (BGI CUSTODY	21,647
JP Morgan (BGI CUSTODY	78,508
JP Morgan (BGI CUSTODY	3,629
Midland Bank (HSBC BANK PLC)	82,625
Northern Trust	66,014
Northern Trust	100,486
Northern Trust	247,331
Northern Trust	140,122
RC Greig Nominees Limited a/c CM1	500
RC Greig Nominees Limited	2,500
RC Greig Nominees Limited	1,030
RC Greig Nominees Limited GP1	550
RC Greig Nominees Limited SA1	5,000
RC Greig Nominees Limited a/c AK1	1,500
RC Greig Nominees Limited a/c BL1	1,500
STATE STREET	14,520
ZEBAN NOMINEES LIMITED	130,310
Group Holding	4,756,886

5. Number of shares/amount of stock acquired

n/a

6. Percentage of issued class

n/a

7. Number of shares/amount of stock disposed

n/a

8. Percentage of issued class

n/a

9. Class of security

Ordinary GBP 0.10 shares

10. Date of transaction

1 November 2006

11. Date Company informed

06 November 2006

12. Total following this notification

4,756,886

13. Total percentage holding of issued class following this notification

16.97%

14. Any additional information

Figures are based on shares in issue of 28,028,004

15. Name of contact and telephone number for queries

16. Name and signature of authorised company official responsible for making this notification

Jenny Owen
Company Secretary
01908 525211

Date of Notification 06 November 2006

This information is provided by RNS
The company news service from the London Stock Exchange

investegate

a Financial Express and Enclave Media partnership

Bepak PLC - Blocklisting

Bepak PLC
06 November 2006

SCHEDULE 5

BLOCKLISTING SIX MONTHLY RETURN

1. Name of company: Bepak plc
2. Name of scheme: Bepak 2002 Executive Share Option Scheme
3. Period of return: From 03 May 2006 to 2 November 2006
4. Number and class of shares(s) (amount of stock/debt security) not issued under scheme at the end of the last period:

1,000,000 ordinary shares

5. Number of shares issued/allotted under scheme during period: 3500
6. Balance under scheme not yet issued/allotted at end of period: 894,750
7. Number and class of share(s) (amount of stock/debt securities) originally listed and the date of admission:

1,000,000 ordinary on 2nd December 2005

Please confirm total number of shares in issue at the end of the period in order for us to update our records:

28,024,704

Contact for queries: Jenny Owen, Company Secretary
Address: Blackhill Drive, Featherstone Road, Wolverton Mill
South, Milton Keynes, Bucks. MK12 5TS

Name of person making return: Jenny Owen
Telephone: 01908 525211

For more information on the Bepak Group please visit our Website at
www.Bepak.com

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bepak PLC - Trading Statement

Bepak PLC
07 November 2006

7 November 2006

Bepak plc

Strong trading in the 26 weeks to 28 October 2006

Bepak plc ('Bepak'), a leader in devices for inhaled drug delivery and anaesthesia, announces strong trading in all its businesses. The performance in the first half year is ahead of its expectations, and providing there is no change in prevailing market conditions, the Board believes that Bepak will exceed its own expectations for the financial year ending 28 April 2007.

Bepak has two business segments: Inhaled Drug Delivery and Anaesthesia & Respiratory Care.

In Inhaled Drug Delivery, Bepak has continued to benefit from strong demand for the Exubera(R) device to deliver Pfizer's inhaled insulin for the treatment of diabetes, which is in the process of being launched worldwide. As long-term patient uptake and acceptance is still unknown, it is difficult to quantify the sales potential for Exubera(R) beyond the increased production levels necessary to support its launch. Bepak has also enjoyed record sales of its MDI valves.

The Anaesthesia & Respiratory Care segment includes King Systems, which was acquired in December 2005. King Systems continues to perform ahead of plan with sales growing in excess of 10% over the prior year. Part of the consideration for the King Systems acquisition was an earn out based on King Systems achieving an agreed level of EBITDA during the year to December 2006. Subject to final verification by the firm's auditors, the Board believes that the performance of King Systems has resulted in the planned earn out being achieved approximately two months ahead of schedule. King Systems is a leading supplier of disposable breathing circuits, masks and laryngeal tubes, mainly sold to hospitals in the US.

Bepak's closure of its loss-making Consumer Products business, announced on 3rd August, is now substantially complete. The sale of certain assets of the business will reduce the non-recurring charge of closure from the previous guidance given of £3m to below £2.5 million and make the exit modestly cash generative.

Bepak will report its interim results on 18 January 2007.

For further information please contact:

Bepak
Mark Throdahl, Chief Executive
Jon Glenn Group Finance Director

Tel: +44 (0)1908 552600

Maitland
Liz Morley

Tel: +44 (0)20 7379 5151

Bepak plc is a leader in specialty medical devices, developing delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings.

The company develops and manufactures a range of devices including metered dose inhalers, dry powder devices, actuators, compliance aids, disposable facemasks, breathing circuits and laryngeal tubes. The group holds the 2005 Frost & Sullivan Award for Technology Innovation and has facilities in King's Lynn and

Milton Keynes in the UK, in Indianapolis, Indiana and Kent, Ohio, in the US and in Mumbai, India. Bepak is a public company quoted on the full list of the London Stock Exchange (LSE: BPK).

This information is provided by RNS
The company news service from the London Stock Exchange



a Financial Express and Inclusive Media partnership

Bepak PLC - Price Monitoring Extension

Bepak PLC
07 September 2006

A Price Monitoring Extension has been activated in this security.

A Price Monitoring Extension is activated when the auction matching process would result in an auction price above or below the base price. The auction call period is extended for

For details of how base prices are set for each market, please refer to the Guide to Trading Services on the London Stock Exchange website www.londonstockexchange.com

Companies House
Crown Way
Cardiff
CF14 3UZ

November 10th 2006

Dear Sirs,

Re Bepak plc Company Registration Number 406711

I enclose herewith Form 88 (2) being a Return of Allotment of Shares in respect of 33,000 10p ordinary shares in the Company allotted to Martin Hopcroft following his exercise of share options.

Please would you acknowledge receipt by stamping and returning the attached copy of this letter using the stamped addressed envelope also enclosed for this purpose.

Yours faithfully

Jenny Owen
Company Secretary



Companies House
— for the record —

88(2)

(Revised 2005)

Return of Allotment of Shares

Please complete in typescript, or
in bold black capitals.

CHWP000

Company Number

406711

Company name in full

BESPAK PLC

Shares allotted (including bonus shares):

(see Guidance Booklet GBA6)

Date or period during which
shares were allotted

(If shares were allotted on one date
enter that date in the "from" box)

From

Day Month Year

0 9 1 1 2 0 0 6

To

Day Month Year

Class of shares

(ordinary or preference etc)

ORDINARY 10P

Number allotted

33,000

Nominal value of each share

10P

Amount (if any) paid or due on each
share (including any share premium)

£2.975

List the names and addresses of the allottees and the
number and class of shares allotted to each overleaf

If the allotted shares (including bonus shares) are fully or partly paid up otherwise than in
cash please state:

% that each share is to be
treated as paid up

% (if any) that each share
is to be paid up in cash

Consideration for which
the shares were allotted

(This information must be supported by
the original or a certified copy of the
contract or by Form 88(3) if the contract
is not in writing)

Companies House receipt date barcode

This form has been provided free of charge
by Companies House.

09/2005

When you have completed and signed the form please send it to the
Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ

for companies registered in England and Wales

or
Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB

for companies registered in Scotland

DX 33050 Cardiff

DX 235 Edinburgh

or LP - 4 Edinburgh 2


Names and addresses of the allottees

Shareholder details <i>(list joint allottees as one shareholder)</i>	Shares and share class allotted	
Name(s) MARTIN HOPCROFT <hr/> Address 1 THEPASTURES, EDLESBOROUGH, DINSTABLE, BEDFORDSHIRE <hr/> <hr/> UK Postcode L U 6 L 2 H L	Class of shares allotted <hr/> ORDINARY 10P <hr/> <hr/>	Number allotted <hr/> 33,000 <hr/> <hr/>
Name(s) <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name(s) <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name(s) <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name(s) <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>

Please enter the number of continuation sheets (if any) attached to this form

x

Signed



Date

10. 11. 06

** A director / secretary / administrator / administrative receiver / receiver / official receiver / receiver manager / voluntary arrangement supervisor

** Please delete as appropriate

Contact Details

You do not have to give any contact information in the box opposite but if you do, it will help Companies House to contact you if there is a query on the form. The contact information that you give will be visible to searchers of the public record.

Ms Jenny Owen, Bepak plc, Blackhill Drive, Featherstone Road,

Wolverton Mill South, Milton Keynes Bucks MK12 5TS

Tel 01908 525211

DX number

DX exchange

Blackhill Drive, Featherstone Road,
Wolverton Mill South, Milton Keynes,
MK12 5TS, England

T: +44 (0) 1908 552600
F: +44 (0) 1908 525260

Companies House
Crown Way
Cardiff
CF14 3UZ

26 September 2006

Dear Sirs,


Re Bepak plc company registration number 406711

I refer to the above company and enclose herewith Form 88 (20 in respect of an allotment of shares to Mr David Billington.

Please would you acknowledge receipt by signing and returning the attached copy of this letter using the stamped addressed envelope also enclosed.

Yours faithfully

Jenny Owen
Company Secretary



THAT with effect from the passing of this resolution, the Articles of Association of the Company are amended by the deletion of Article 148, and replacement of it with the following article:

148 "Indemnity"

148.1 Subject to the provisions of, and so far as may be permitted by, the Statutes but without prejudice to any indemnity to which the person concerned may be otherwise entitled, the Company may indemnify every director, alternate director, auditor, secretary or other officer of the Company entitled to be indemnified by the Company against all costs, charges, losses, expenses and liabilities incurred by him in the execution and discharge of his duties or the exercise of his powers or otherwise in relation to or in connection with his duties, powers or office including any liability which may attach to him in respect of any negligence, default, breach of duty or breach of trust in relation to anything done or omitted to be done by him as a director, alternate director, auditor, secretary or other officer of the Company.

148.2 The directors may purchase and maintain at the cost of the Company insurance cover for or for the benefit of every director, alternate director, auditor, secretary or other officer of the Company or of any associated company (as defined in the Act) against any liability which may attach to him in respect of any negligence, default, breach of duty or breach of trust by him in relation to the Company (or such associated company) including anything done or omitted to be done or alleged to have been done or omitted to be done by him as a director, alternate director, auditor, secretary or other officer of the Company or any associated company.

148.3 Subject to the provisions of, and as far as may be permitted by, the Statutes, the Company shall be entitled to fund the expenditure of every director, alternate director or other officer of the Company incurred or to be incurred:

148.3.1 In defending any criminal or civil proceedings: or

148.3.2 In connection with any application under sections 144 (3), 144(4) or 727 of the Act.

148.4 For the purposes of this Article 148, "Statutes" shall mean the Act and every other statute, order, regulation, instrument or other subordinate legislation for the time being in force relating to companies and affecting the Company.

BESPAK plc

Minutes of the 47th Annual General Meeting of Bepak plc held at Blackhill Drive, Featherstone Road, Wolverton Mill South, Milton Keynes, Bucks. MK12 on Thursday 28 September, 2006 at 2.00 pm.

1. INTRODUCTION

The Chairman welcomed shareholders to the Meeting and introduced the Directors.

2. TRADING STATEMENT

The Chairman then read out a trading statement which was had been on the morning of the Annual General Meeting.

The Chairman requested that the Notice convening the Meeting be taken as read, which was agreed, and then explained the voting procedure.

3. RESOLUTION 1: ADOPTION OF ACCOUNTS

The Report of the Auditors to members was taken as read. The Chairman asked if there were any further questions on the Report and Accounts. There being no questions the Resolution was put to the Meeting and carried unanimously on a show of hands.

Proxy votes were received as follows:

17,859,551 in favour

0 against

3,855 gave discretion to the Chairman

0 abstained.

4. RESOLUTION 2: FINAL DIVIDEND

The Resolution was put to the Meeting and carried unanimously on a show of hands.

Proxy votes were received as follows:

17,859,551 in favour

0 against

3,855 gave discretion to the Chairman

0 abstained.

5. RESOLUTION 3: RE-ELECTION OF MR JOHN ROBINSON

The Resolution was put to the Meeting and carried unanimously on a show of hands.

Proxy votes were received as follows:

17,850,759 were in favour

8,313 against

3,855 gave discretion to the Chairman

479 abstained

6. RESOLUTION 4: RE-ELECTION OF MR MARK THRODAHL

The Resolution was put to the Meeting and carried unanimously on a show of hands.
Proxy votes were received as follows:
17,858,759 were in favour
313 against
3,855 gave discretion to the Chairman
479 abstained.

7. RESOLUTION 5: ELECTION OF MR PAUL BOUGHTON

The Resolution was put to the Meeting and carried unanimously on a show of hands.
Proxy votes were received as follows:
17,857,659 were in favour
613 against
4,655 gave discretion to the Chairman
479 abstained.

8. RESOLUTION 6: ELECTION OF MR JONATHAN GLENN

The Resolution was put to the Meeting and carried unanimously on a show of hands.
Proxy votes were received as follows:
17,849,609 were in favour
8,613 against
3,855 gave discretion to the Chairman
1,329 abstained.

9. RESOLUTION 7: ELECTION OF DR PETER FELLNER

The Resolution was put to the Meeting and carried unanimously on a show of hands.
Proxy votes were received as follows:
17,440,836 were in favour
275,530 against
4,395 gave discretion to the Chairman
142,645 abstained.

10. RESOLUTION 8: ELECTION OF MR JIM DICK

The Resolution was put to the Meeting and carried unanimously on a show of hands.
Proxy votes were received as follows:
17,858,219 were in favour
313 against
4,395 gave discretion to the Chairman
479 abstained

11. RESOLUTION 9: ELECTION OF MR CHRIS BANKS

The Resolution was put to the Meeting and carried unanimously on a show of hands.
Proxy votes were received as follows:
17,858,219 were in favour
313 against

4,395 gave discretion to the Chairman
479 abstained.

12. RESOLUTION 10: REMUNERATION REPORT

The Resolution was then put to the Meeting and carried unanimously on a show of hands.
Proxy votes were received as follows:
17,363,230 were in favour
197,616 against
5,101 gave discretion to the Chairman
297,459 abstained.

13. RESOLUTION 11: RE-APPOINTMENT OF AUDITORS

The Resolution was put to the Meeting and carried unanimously on a show of hands.
Proxy votes were received as follows:
17,583,037 were in favour
275,696 against
4,641 gave discretion to the Chairman
32 abstained.

14. RESOLUTION 12: SECTION 80 AUTHORITY

The Resolution was put to the Meeting and carried unanimously on a show of hands.
Proxy votes were received as follows:
17,849,673 were in favour
8,300 against
4,954 gave discretion to the Chairman
479 abstained.

15. RESOLUTION 13: DISAPPLICATION OF PRE-EMPTION RIGHTS

The Resolution was put to the Meeting and passed as a Special Resolution.
Proxy votes were received as follows:
17,850,226 were in favour
8,600 against
4,101 gave discretion to the Chairman
479 abstained.

16. RESOLUTION 14: MARKET PURCHASE

The Resolution was put to the Meeting and passed as a Special Resolution.
Proxy votes were received as follows:
17,858,713 were in favour
0 against
4,101 gave discretion to the Chairman
592 abstained.

17. RESOLUTION 15: AMENDMENT TO ARTICLES OF ASSOCIATION

The Resolution was put to the Meeting and carried unanimously on a show of hands.

Proxy votes were received as follows:

17,583,496 were in favour

275,696 against

4,101 gave discretion to the Chairman

113 abstained.

18. CONCLUSION

There being no further business the Chairman declared the formal business of the Meeting closed.

Chairman

Blackhill Drive, Featherstone Road,
Wolverton Mill South, Milton Keynes,
MK12 5TS, England

T: +44 (0) 1908 552600
F: +44 (0) 1908 525260

Companies House
Crown Way
Cardiff
CF14 3UZ

October 18 2006

Dear Sirs


Re Bepak plc Company Number 406711 Annual Return

I return herewith the completed Annual Return for the above company together with our cheque in the sum of £30 being the fee thereon and a cd containing the list of shareholders as at 20 September 2006.

I would be grateful if you would kindly acknowledge receipt by stamping and returning the attached copy of this letter using the stamped, addressed envelope enclosed for this purpose.

Yours faithfully

Jenny Owen
Company Secretary



The Company Secretary
BESPAK PLC
Blackhill Drive Featherstone
Road Wolverton Mill South
Milton Keynes
Buckinghamshire MK12 5TS

57419-00396



Our Ref 406711/09/28
Date 19th September 2006

Crown Way Cardiff CF14 3UZ
Telephone 0870 3333636
Fax 029 2038 0900
DX 33050 Cardiff

2006 Annual Return for Company Number 406711

Your company's 2006 Annual Return is attached to this letter. It shows the information Companies House held on **15th September 2006** about your company and makes provision for you to enter certain details that are not already held.

What you should do

- Check the information already pre-printed on the Annual Return
- Enter any changes to that information in the spaces provided
- Complete section 3 and provide a full list of shareholders or, list of changes to the company shareholders as appropriate
- Complete and sign the Declaration
- **Return the full Annual Return and your shareholder list, if appropriate, with the fee payment.**

Important dates

Please make sure that the information you give us:

- Confirms your company's details as at **20th September 2006 the return date**
- Reaches Companies House by **18th October 2006 at the latest**

Returning the form

Failure to deliver an Annual Return on time is a criminal offence and may result in the prosecution of your company and its officers or the company being struck off the register. This applies to all companies, **even those which have not been trading.**

Company no longer required?

If the company is not trading and is no longer required, let us know by telephoning 0870 3333636.

The fee

The fee for the Annual Return is £30. Please send a cheque made payable to Companies House with your completed Annual Return.



GUARDED FOR EXCELLENCE



P.T.O



Companies House

for the record

any Name

PAK PLC

363s Annual Return

- > Please check the details printed in blue on this statement.
- > If any details are wrong, strike them through and write the correct details in the "Amended details" column.
- > Please use black pen and write in capitals.

Company Type
Public Limited Company

Company Number
6711

Information extracted from
Companies House records on
15th September 2006

Section 1: Company details

406711/09/28

Current details		Amended details																					
Registered Office Address <i>If any of the details are wrong, strike them through and fill in the correct details in the "Amended details" column.</i>	Blackhill Drive Featherstone Road Wolverton Mill South Milton Keynes Buckinghamshire MK12 5TS	Address _____ _____ _____ UK Postcode _ _ _ _ _																					
Register of Members <i>If any of the details are wrong, strike them through and fill in the correct details in the "Amended details" column.</i>	Address where the Register is held Capita Registrars The Registry 34 Beckenham Road Beckenham Kent BR3 4TU	Address _____ _____ _____ UK Postcode _ _ _ _ _																					
Register of Debenture Holders <i>If any of the details are wrong, strike them through and fill in the correct details in the "Amended details" column.</i>	Not Applicable	Address _____ _____ _____ UK Postcode _ _ _ _ _																					
Principal Business Activities <i>If any of the details are wrong, strike them through and fill in the correct details in the "Amended details" column.</i>	<table border="1"><thead><tr><th>SIC Code</th><th>Description</th></tr></thead><tbody><tr><td>3310</td><td>Mfr medical, orthopaedic etc equip</td></tr><tr><td>7415</td><td>Holding companies incl head offices</td></tr></tbody></table>	SIC Code	Description	3310	Mfr medical, orthopaedic etc equip	7415	Holding companies incl head offices	<table border="1"><thead><tr><th>SIC CODE</th><th>Description</th></tr></thead><tbody><tr><td>_____</td><td>_____</td></tr><tr><td>_____</td><td>_____</td></tr><tr><td>_____</td><td>_____</td></tr><tr><td>_____</td><td>_____</td></tr><tr><td>_____</td><td>_____</td></tr><tr><td>_____</td><td>_____</td></tr></tbody></table>	SIC CODE	Description	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	
SIC Code	Description																						
3310	Mfr medical, orthopaedic etc equip																						
7415	Holding companies incl head offices																						
SIC CODE	Description																						
_____	_____																						
_____	_____																						
_____	_____																						
_____	_____																						
_____	_____																						
_____	_____																						

Please enter additional
principal activity code(s) in
"Amended details" column.
Notes for guidance for
activity codes.

VICE

P.

Section 2: Details of Officers of the Company

	Current details	Amended details
<p>Company Secretary</p> <p><i>If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.</i></p> <p><i>Particulars of a new Company Secretary must be notified on form 288a.</i></p>	<p>Name</p> <p>Jennifer Margaret OWEN</p> <p>Address</p> <p>138 Clarence Road St. Albans Hertfordshire AL1 4NW</p>	<p>Name</p> <p>_____</p> <p><input type="checkbox"/> Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.</p> <p>Address</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>UK Postcode _ _ _ _ _</p> <p>Date of change _ _ / _ _ / _ _ _ _</p> <p>Date Jennifer Margaret OWEN ceased to be secretary (if applicable)</p> <p> _ _ / _ _ / _ _ _ _</p>
<p>Director</p> <p><i>If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.</i></p> <p><i>Particulars of a new Director must be notified on form 288a.</i></p>	<p>Name</p> <p>John Christopher BANKS</p> <p>Address</p> <p>Copyhold Lock Lane Partridge Green West Sussex RH13 8EF</p> <p>Date of birth 04/03/1950</p> <p>Nationality British</p> <p>Occupation Director</p>	<p>Name</p> <p>_____</p> <p><input type="checkbox"/> Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.</p> <p>Address</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>UK Postcode _ _ _ _ _</p> <p>Date of birth _ _ / _ _ / _ _ _ _</p> <p>Nationality _____</p> <p>Occupation _____</p> <p>Date of change _ _ / _ _ / _ _ _ _</p> <p>Date John Christopher BANKS ceased to be director (if applicable)</p> <p> _ _ / _ _ / _ _ _ _</p>

Section 2: Details of Officers of the Company (continued)

Current details

Amended details

If the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.

Name
Paul Victor BOUGHTON

Address
11 Esher Place Avenue
Esher
Surrey
KT10 8PU

Date of birth 29/09/1955

Nationality British

Occupation Company Director

Particulars of a new Director must be notified on form 288a.

Name

☐ Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.

Address

UK Postcode

Date of birth

Nationality

Occupation

Date of change

Date Paul Victor BOUGHTON ceased to be director (if applicable)

Director

If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.

Name
John Patrick CASHMAN

Address
51 Wellington Road
Dublin 4
Eire
Ireland

Date of birth 19/11/1940

Nationality Irish

Occupation Director

Particulars of a new Director must be notified on form 288a.

Name

☐ Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.

Address

UK Postcode

Date of birth

Nationality

Occupation

Date of change

Date John Patrick CASHMAN ceased to be director (if applicable)

	Current details	Amended details
<p>> Director If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.</p> <p>Particulars of a new Director must be notified on form 288a.</p>	<p>Name James Lawrence DICK</p> <p>Address Broomhill 16A Humber Road North Ferriby North Humberside HU14 3DW</p> <p>Date of birth 21/10/1952</p> <p>Nationality British</p> <p>Occupation Director</p>	<p>Name</p> <p><input type="checkbox"/> Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.</p> <p>Address</p> <p>UK Postcode _ _ _ _ _</p> <p>Date of birth _ _ / _ _ / _ _ _ _</p> <p>Nationality _ _ _ _ _</p> <p>Occupation _ _ _ _ _</p> <p>Date of change _ _ / _ _ / _ _ _ _</p> <p>Date James Lawrence DICK ceased to be director (if applicable) _ _ / _ _ / _ _ _ _</p>
<p>> Director If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.</p> <p>Particulars of a new Director must be notified on form 288a.</p>	<p>Name Dr Peter John FELLNER</p> <p>This is a service address for the beneficiary of a Confidentiality Order.</p> <p>Address Vernalis Plc, Oakdene Court 613 Reading Road Winnersh Berkshire RG41 5UA</p> <p>Date of birth 31/12/1943</p> <p>Nationality British</p> <p>Occupation Company Director</p>	<p>Name</p> <p><input type="checkbox"/> Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.</p> <p>Address</p> <p>UK Postcode _ _ _ _ _</p> <p>Date of birth _ _ / _ _ / _ _ _ _</p> <p>Nationality _ _ _ _ _</p> <p>Occupation _ _ _ _ _</p> <p>Date of change _ _ / _ _ / _ _ _ _</p> <p>Date Dr Peter John FELLNER ceased to be director (if applicable) _ _ / _ _ / _ _ _ _</p>

Section 2: Details of Officers of the Company (continued)

Current details

Amended details

If the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.

Name
William George MEREDITH

Address
8484 Lake Elmo Avenue North
Stillwater
Minnesota 55082
Usa

Date of birth 10/09/1943

Nationality American

Occupation Director

Name

☐ Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.

Address

UK Postcode _ _ _ _ _

Date of birth _ _ / _ _ / _ _ _ _

Nationality _ _ _ _ _

Occupation _ _ _ _ _

Date of change _ _ / _ _ / _ _ _ _

Date William George MEREDITH
ceased to be director (if applicable)

_ _ / _ _ / _ _ _ _

Particulars of a new Director must be notified on form 288a.

Director

If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.

Name
John Harris ROBINSON

Address
20 Mill Lane
Elloughton
Brough
East Yorkshire
HU15 1JL

Date of birth 22/12/1940

Nationality British

Occupation Director

Name

☐ Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985.

Address

UK Postcode _ _ _ _ _

Date of birth _ _ / _ _ / _ _ _ _

Nationality _ _ _ _ _

Occupation _ _ _ _ _

Date of change _ _ / _ _ / _ _ _ _

Date John Harris ROBINSON
be director (if applicable)

_ _ / _ _ / _ _ _ _

Particulars of a new Director must be notified on form 288a.

> Director

If any of the details for this person are wrong, strike them through and fill in the correct details in the "Amended details" column.

Particulars of a new Director must be notified on form 288a.

Current details	Amended details
Name Mark Crandall THRODAHL	Name
Address 38 Carteret Road Allendale New Jersey 07401 Usa	<input type="checkbox"/> Tick this box if this address is a service address for the beneficiary of a Confidentiality Order granted under section 723B of the Companies Act 1985. Address
Date of birth 30/03/1951	UK Postcode _ _ _ _ Date of birth _ _ / _ _ / _ _ _ _ Nationality _____ Occupation _____ Date of change _ _ / _ _ / _ _ _ _ Date Mark Crandall THRODAHL ceased to be director (if applicable) _ _ / _ _ / _ _ _ _

Director.

JONATHAN GLENN

Appointed 26.7.06

48 HAZEL ROAD
PARK STREET
ST ALBANS
HERTS.
AL2 2AT.

Appointed 26/7/06

DATE OF BIRTH 13/11/1968.

NATIONALITY BRITISH.

OCCUPATION FINANCE DIRECTOR

DIRECTOR

GEORGE MACDONALD KENNEDY

Appointed 31.8.06.

BESPAK PLC
BLACKHILL DRIVE
FEATHERSTONE ROAD
WOLLERSON HILL SOUTH
MILSON KEYNES MK12 5TS.

DATE OF BIRTH 04/08/1940.

NATIONALITY
OCCUPATION

BRITISH.
COMPANY DIRECTOR.

MR KENNEDY IS THE BENEFICIARY OF A CONFIDENTIALITY ORDER. THIS ADDRESS IS A SERVICE ADDRESS

Appointed 31/08/06

Section 3: Share Capital

(C)

Issued share capital details

Please fill in the details of total share capital by class (eg. ordinary, preference etc) that has been issued to the company's shareholders.

Class of Share

ORDINARY x 10p

Number of shares issued

28,021,204⁰¹⁸

Aggregate Nominal Value of issued shares

£28,021,204⁰¹⁸

Class of Share

Number of shares issued

Aggregate Nominal Value of issued shares

Class of Share

Number of shares issued

Aggregate Nominal Value of issued shares

Class of Share

Number of shares issued

Aggregate Nominal Value of issued shares

> Please fill in the total number of issued shares and their total nominal value.

Number of shares issued

28,021,204⁰¹⁸

Aggregate Nominal Value of issued shares

£28,021,204⁰¹⁸

st of past and present members (Tick appropriate box)

Please complete the required information on the attached schedules or in another format agreed by Companies House.

- ☐ There were no changes during the period
- ☐ A list of changes is enclosed
- ☒ A full list of members is enclosed

The last full list of members was received on: 20/09/2005

REMEMBER:

Changes to shareholder particulars or details of shares transferred to be completed each year
A full list of shareholders is required with the first and every third Annual Return thereafter
List shareholders in alphabetical order or provide an index
List joint shareholders consecutively



Companies House

— for the record —

363s Annual Return Declaration

- > When you have checked all the sections of this form, please complete this page and sign the declaration below.
- > If you want to change the made up date of this annual return, please complete 2 below.

1. Declaration

- ☐ I confirm that the details in this annual return are correct as at the made-up-date (shown at 2 below). I enclose the filing fee of £30.

Signature

J. M. Owen
(Director / Secretary)

Date 20 / 09 / 2006

This date must not be earlier than the
return date at 2 below

What to do now

Complete this page then send the whole of the Annual Return and the
declaration to the address shown at 4 below.

2. Date of this return

- ☒ This AR is made up to 20/9/2006 If you are making this return up to an earlier date,
please give the date here

__ / __ / ____

Note: The form must be delivered to CH within 28 days of this date

3. Date of next return

- ☐ If you wish to change your next return to a date earlier than 20th September
2007 please give the new date here:

__ / __ / ____

4. Where to send this form

- ☐ Please return this form to:

Registrar of Companies
Companies House
Crown Way
Cardiff CF14 3UZ

OR

For members of the Hays Document
Exchange service
DX 33050 Cardiff

Have you enclosed the filing fee with the company number written on the
reverse of the cheque?

Contact Address

You do not have to give any contact information below, but if you do, it will help
Companies House to contact you if there is a query on the form. The contact
information that you give will be visible to searchers of the public record.

Contact Name

MS. J. M. OWEN

Telephone number inc code

01908 525211

Address

BLACKHILL PRIVE
FEATHERSTONE ROAD
WOLVERSON MILL SOUTH
MILTON KEYNES

DX number if applicable

DX exchange

Postcode

MK12 5TS

Blackhill Drive, Featherstone Road,
Wolverton Mill South, Milton Keynes,
MK12 5TS, England

T: +44 (0) 1908 552600
F: +44 (0) 1908 525260

Companies House
Crown Way
Cardiff
CF14 3UZ

26 September 2006

Dear Sirs,


Re Bespak plc company registration number 406711

I refer to the above company and enclose herewith Form 88 (20 in respect of an allotment of shares to Mr David Billington.

Please would you acknowledge receipt by signing and returning the attached copy of this letter using the stamped addressed envelope also enclosed.

Yours faithfully

Jenny Owen
Company Secretary





Companies House
— for the record —

88(2)

(Revised 2005)

Return of Allotment of Shares

Please complete in typescript, or
in bold black capitals.

CHWP000

Company Number

406711

Company name in full

BESPAK PLC

Shares allotted (including bonus shares):

(see Guidance Booklet GBA6)

Date or period during which
shares were allotted

(If shares were allotted on one date
enter that date in the "from" box)

From

Day Month Year

2 6 0 9 2 0 0 6

To

Day Month Year

Class of shares

(ordinary or preference etc)

ORDINARY 10P

Number allotted

186

Nominal value of each share

10P

Amount (if any) paid or due on each
share (including any share premium)

£4.34

List the names and addresses of the allottees and the
number and class of shares allotted to each overleaf

If the allotted shares (including bonus shares) are fully or partly paid up otherwise than in
cash please state:

% that each share is to be
treated as paid up

% (if any) that each share
is to be paid up in cash

Consideration for which
the shares were allotted

(This information must be supported by
the original or a certified copy of the
contract or by Form 88(3) if the contract
is not in writing)

Companies House receipt date barcode

This form has been provided free of charge
by Companies House.

09/2005

When you have completed and signed the form please send it to the
Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ
for companies registered in England and Wales

or
Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB
for companies registered in Scotland

DX 33050 Cardiff

DX 235 Edinburgh
or LP - 4 Edinburgh 2

Names and addresses of the allottees

Shareholder details <i>(list joint allottees as one shareholder)</i>	Shares and share class allotted	
Name(s) DAVID BILLINGTON <hr/> Address 5 LITTLE PARK, BOVINGDON, HEMEL HEMPSTEAD, HERTFORDSHIRE <hr/> UK Postcode H P 3 0 J B L	Class of shares allotted <hr/> ORDINARY 10P <hr/>	Number allotted <hr/> 186 <hr/>
Name(s) <hr/> Address <hr/> <hr/> <hr/> UK Postcode L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name(s) <hr/> Address <hr/> <hr/> <hr/> UK Postcode L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name(s) <hr/> Address <hr/> <hr/> <hr/> UK Postcode L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name(s) <hr/> Address <hr/> <hr/> <hr/> UK Postcode L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>

Please enter the number of continuation sheets (if any) attached to this form

Signed _____ Date _____

** A director / secretary / administrator / administrative receiver / receiver / official receiver / receiver manager / voluntary arrangement supervisor

** Please delete as appropriate

Contact Details

You do not have to give any contact information in the box opposite but if you do, it will help Companies House to contact you if there is a query on the form. The contact information that you give will be visible to searchers of the public record.

MISS JENNY OWEN, BESPAC PLC, BLACKHILL DRIVE	
FEATHERSTONE ROAD, WOLVERTON MILL SOUTH	
MILTON KEYNES MK12 5TS	Tel 01908 525211
DX number	DX exchange

Companies House
Crown Way
Cardiff
CF14 3UZ

June 14th 2006

Dear Sirs,

re Bepak PLC Company number 406711

I refer to the above company and enclose herewith form 288a in respect of the appointment of a new director of the company.

Please acknowledge receipt by stamping and returning the attached copy of this letter to indicate safe receipt. I enclose a stamped addressed envelope for this purpose.

Yours faithfully,

Jennifer M Owen
Company Secretary and General Counsel



Companies House

- for the record -

Please complete in typescript,
or in bold black capitals.

CHWP000

288a

APPOINTMENT of director or secretary (NOT for resignation (use Form 288b) or change of particulars (use Form 288c))

Company Number

406711

Company Name in full

BESPAK PLC

Date of
appointment

Day Month Year
01 06 2006

†Date of
Birth

Day Month Year
29 09 1955

Appointment form Appointment as director

☒

as secretary

☐

Please mark the appropriate box. If appointment is
as a director and secretary mark both boxes.

Notes on completion
appear on reverse.

NAME

*Style / Title

MR.

*Honours etc

Forename(s)

PAUL VICTOR

Surname

BOUGHTON

Previous
Forename(s)

Previous
Surname(s)

†† Tick this box if the
address shown is a
service address for
the beneficiary of a
Confidentiality Order
granted under the
provisions of section
723B of the
Companies Act 1985

†† Usual residential
address

☐

Post town

11 ESHER PLACE AVENUE

ESHER

Postcode

KT10 8PU

County / Region

SURREY

Country

ENGLAND

†Nationality

ENGLISH

†Business occupation

COMPANY DIRECTOR

†Other directorships
(additional space overleaf)

RAYMARINE PLC; GOM MARINE SERVICES LTD

Consent signature

I consent to act as ** director / secretary of the above named company

Date

14.06.2006

* Voluntary details.

† Directors only.

**Delete as appropriate

A director, secretary etc must sign the form below.

Signed

J. M. Owen

Date

14.06.2006

(*a director / secretary / administrator / administrative receiver / receiver manager / receiver)

You do not have to give any contact
information in the box opposite but if you
do, it will help Companies House to
contact you if there is a query on the
form. The contact information that you
give will be visible to searchers of the
public record.

MS. J. M. OWEN. BESPAK PLC, BLACKHILL DRIVE

FEATHERSTONE ROAD, WOLLERTON MILL SOUTH

MILTON KEYNES

MK1253

Tel 01908 525211

DX number

DX exchange

Companies House receipt date barcode

This form has been provided free of charge
by Companies House

When you have completed and signed the form please send it to the
Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ DX 33050 Cardiff
for companies registered in England and Wales or

Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB

for companies registered in Scotland

DX 235 Edinburgh

or LP - 4 Edinburgh 2

Company Number

406711

† Directors only.

† Other directorships

ESTHER PLACE RESIDENTS LIMITED

PREVIOUS ; SPECTRIS PLC ; LONDON BRIDGE

SOFTWARE HOLDINGS PLC

NOTES

Show the full forenames, NOT INITIALS. If the director or secretary is a corporation or Scottish firm, show the name on surname line and registered or principal office on the usual residential line.

Give previous forenames or surname(s) except:

- for a married woman, the name by which she was known before marriage need not be given.
- for names not used since the age of 18 or for at least 20 years

A peer or individual known by a title may state the title instead of or in addition to the forenames and surname and need not give the name by which that person was known before he or she adopted the title or succeeded to it.

Other directorships.

Give the name of every company incorporated in Great Britain of which the person concerned is a director or has been a director at any time in the past five years.

You may exclude a company which either is, or at all times during the past five years when the person concerned was a director, was

- dormant
- a parent company which wholly owned the company making the return, or
- another wholly owned subsidiary of the same parent company.

Companies House
Crown Way
Cardiff
CF14 3NZ

7th August 2006

Dear Sirs,

Re Company Number 406711 Bepak PLC

I refer to the above company and enclose herewith Form 88(2). Please would you acknowledge receipt by stamping and returning the attached copy of this letter using the stamped addressed envelope enclosed for this purpose.

Yours faithfully

Jenny Owen
Company Secretary and Group Counsel.

Names and addresses of the allottees

Shareholder details (list joint allottees as one shareholder)		Shares and share class allotted	
Name(s) MRS PAMELA LONSDALE.	Class of shares allotted	Number allotted	
Address 25 SRAFTON ROAD	ORDINARY 10p	450.	
REFLECT ESTATE			
KINGS LYNN UK Postcode PE303HA.			
Name(s)	Class of shares allotted	Number allotted	
Address			
UK Postcode			
Name(s)	Class of shares allotted	Number allotted	
Address			
UK Postcode			
Name(s)	Class of shares allotted	Number allotted	
Address			
UK Postcode			
Name(s)	Class of shares allotted	Number allotted	
Address			
UK Postcode			

Please enter the number of continuation sheets (if any) attached to this form

Signed J. M. Owen

Date 7.8.06

** A director / secretary / administrator / administrative receiver / receiver / official receiver / receiver manager / voluntary arrangement supervisor.

** Please delete as appropriate

Contact Details

You do not have to give any contact information in the box opposite but if you do, it will help Companies House to contact you if there is a query on the form. The contact information that you give will be visible to searchers of the public record.

MISS J. M. OWEN. c/o BESPAK PIC	
BLACKHILL DRIVE, FEATHERSTONE ROAD,	
WOLVERSON MILL SOUTH, MILTON KEYNES	
MK12 5JS.	Tel 01908 525211
DX number	DX exchange



Companies House

— for the record —

Please complete in typescript, or
in bold black capitals.

CHWP000

Company Number

406711

Company name in full

BESPAK PLC

88(2)

(Revised 2005)

Return of Allotment of Shares

Shares allotted (including bonus shares):

(see Guidance Booklet GBA6)

Date or period during which
shares were allotted
(If shares were allotted on one date
enter that date in the "from" box)

From

Day Month Year

07 08 2006

To

Day Month Year

Class of shares
(ordinary or preference etc)

ORDINARY

Number allotted

450.

Nominal value of each share

10p.

Amount (if any) paid or due on each
share (including any share premium)

£3.18.

List the names and addresses of the allottees and the
number and class of shares allotted to each overleaf

If the allotted shares (including bonus shares) are fully or partly paid up otherwise than in
cash please state:

% that each share is to be
treated as paid up

% (if any) that each share
is to be paid up in cash

Consideration for which
the shares were allotted

(This information must be supported by
the original or a certified copy of the
contract or by Form 88(3) if the contract
is not in writing)

Companies House receipt date barcode

This form has been provided free of charge
by Companies House.

09/2005

When you have completed and signed the form please send it to the
Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ

for companies registered in England and Wales

or
Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB

for companies registered in Scotland

DX 33050 Cardiff

DX 235 Edinburgh

or LP - 4 Edinburgh 2

6espak plc

Annual Information Update

In accordance with Prospectus Rule 5.2, the following information has been published or made available to the public in the 12 months up to and including 18 August 2006.

The following announcements have been made via RNS, a Regulatory Information Service.

Date of Announcement	Regulatory Headline
25 August 2005	Financial Calendar
8 September 2005	AGM statement
9 September 2005	Result of AGM
30 September 2005	Blocklisting Interim Review
4 October 2005	New Company Secretary
11 October 2005	Share Incentive Plan
14 October 2005	Exubera Update
24 October 2005	Block listing interim review
26 October 2005	Block listing interim review
8 November 2005	Share Incentive Plan
14 November 2005	Peter Fellner Appointment
14 November 2005	Trading Statement
2 December 2005	Additional Listing
6 December 2005	Posting of Circular
6 December 2005	Proposed Acquisition
8 December 2005	Director/PDMR Holding
22 December 2005	Result of EGM
23 December 2005	Acquisition and Blocklisting
4 January 2006	Notification of shares
4 January 2006	Notification of shares
4 January 2006	Notice of Results
6 January 2006	Holding(s) in Company
10 January 2006	Director/PDMR Holding
13 January 2006	Adoption of IFRS
18 January 2006	Interim Results
24 January 2006	Blocklisting Return
27 January 2006	Director/PDMR Holding
27 January 2006	Exubera Regulatory Approval
30 January 2006	Exubera Approval in US
6 February 2006	Director/PDMR Holding
9 March 2006	Company Secretary Change
14 March 2006	Director Share Purchase
27 March 2006	Director/PDMR Shareholding

30 March 2006	Block Listing Review
4 April 2006	Holding(s) in Company
19 April 2006	Holding(s) in Company
24 April 2006	Blocklisting Review
25 April 2006	Blocklisting Review
26 April 2006	Board Changes
26 April 2006	Director Share Purchase
2 May 2006	Director/PDMR Shareholding
2 May 2006	Blocklisting Review
10 May 2006	PDMR Shareholding
11 May 2006	Holding(s) in Company
12 May 2006	Director/PDMR Shareholding
22 May 2006	Holding(s) in Company
30 May 2006	Holding(s) in Company
2 June 2006	Directorate Change
20 June 2006	Facility Visit
28 June 2006	Holding(s) in Company
30 June 2006	Holding(s) in Company
12 July 2006	Final Results
13 July 2006	Director/PDMR Shareholding
14 July 2006	Holding(s) in Company
25 July 2006	Blocklisting Review
27 July 2006	Change of Director
28 July 2006	Holding(s) in Company
3 August 2006	Close of HPC Business
4 August 2006	Director/PDMR Shareholding
11 August	Holding(s) in Company

In accordance with the provisions of Article 27.3 of the Prospectus Directive Regulation, we confirm that to the best of our knowledge, information relating to "Holdings in Company", "Directors' Shareholdings" and "Director/PDMR Shareholdings" is up to date at the date of this announcement but it is acknowledged that such disclosures may, at any time, become out of date, due to changing circumstances.

Details of all regulatory announcements for Bepak plc can be found on the prices page of the London Stock Exchange website at www.londonstockexchange.com and any related documents are available at the UKLA's Document Viewing Facility, Financial Services Authority, 25 The Colonnade, Canary Wharf, London E14 5HS.

The Company has also made the following filings with Companies House:

Date of Filing	Document filed
9 September 2005	Resignation of Director
15 September 2005	Return of Allotment of Shares

15 September 2005	Return of Allotment of Shares
15 September 2005	Return of Allotment of Shares
15 September 2005	Return of Allotment of Shares
23 September 2005	Return of Allotment of Shares
26 September 2005	Annual Return
30 September 2005	Appointment of Company Secretary
30 September 2005	Resignation of Company Secretary
1 November 2005	Return of Allotment of Shares
4 November 2005	Return of Allotment of Shares
17 November 2005	Appointment of Director
14 December 2005	Return of Allotment of Shares
9 January 2006	Return of Allotment of Shares
27 January 2006	Return of Allotment of Shares
28 January 2006	Return of Allotment of Shares
30 January 2006	Appointment of Director
6 February 2006	Return of Allotment of Shares
8 March 2006	Return of Allotment of Shares
21 March 2006	Appointment of Company Secretary
21 March 2006	Resignation of Company Secretary
11 May 2006	Return of Allotment of Shares
14 June 2006	Appointment of Director
16 June 2006	Resignation of Director
16 June 2006	Appointment of Director
11 August	Resignation of Director

Copies of these documents can be obtained from Companies House or through Companies House Direct at www.direct.companieshouse.gov.uk

Further information is available regarding the Company and its activities on its website at www.bespak.com.

The Bepak plc Annual Report 2005 and the AGM circular was filed with the UKLA Document Viewing Facility on 15 August 2005 and can also be found on the Company's website or on application to the Company Secretary. The Bepak plc Annual Report 2006 and AGM Circular will be posted on or about 25th August 2006 and will also be posted on the Company's website and will be available from the Company Secretary upon application.

Jenny Owen
Company Secretary
01908 525211

18 August 2006



Companies House
for the record

Please complete in typescript,
or in bold black capitals.

CHWP000

288a

APPOINTMENT of director or secretary (NOT for resignation (use Form 288b) or change of particulars (use Form 288c))

Company Number

406711

Company Name in full

BESPAK PLC

Date of
appointment

Day Month Year
29 08 2006

†Date of
Birth

Day Month Year
04 08 1940

Appointment form Appointment as director ☒ as secretary ☐

Please mark the appropriate box. If appointment is as a director and secretary mark both boxes.

NAME

*Style / Title

Mr

*Honours etc

CBE

Notes on completion
appear on reverse.

Forename(s)

GEORGE

MACDONALD

Surname

KENNEDY

Previous
Forename(s)

Previous
Surname(s)

†† Tick this box if the
address shown is a
service address for
the beneficiary of a
Confidentiality Order
granted under the
provisions of section
723B of the
Companies Act 1985

†† Usual residential
address



Post town

MILTON KEYNES

Postcode

MK12 5TS

County / Region

Country

†Nationality

BRITISH

†Business occupation

DIRECTOR

†Other directorships
(additional space overleaf)

E2V PLC / VERNALIS PLC / ISOTRON PLC

Consent signature

I consent to act as *director / secretary of the above named company

[Signature]

Date

29 Aug 2006

* Voluntary details.

† Directors only.

**Delete as appropriate

A director, secretary etc must sign the form below.

Signed

[Signature]

Date

7 September 2006

(*a director / secretary / administrator / administrative receiver / receiver-manager / receiver)

JENNIFER OWEN, COMPANY SECRETARY

BESPAK PLC, BLACKHILL DRIVE, FEATHERSTONE ROAD,
WOLVERTON MILL SOUTH, MILTON KEYNES, BUCKS.

MK12 5TS

Tel 01908 525211

DX number

DX exchange

Companies House receipt date barcode

This form has been provided free of charge
by Companies House

Form 10/03

When you have completed and signed the form please send it to the
Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ DX 33050 Cardiff
for companies registered in England and Wales or
Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB
for companies registered in Scotland

DX 235 Edinburgh
or LP - 4 Edinburgh 2

Company Number

406711

Directors only.

Other directorships

SPACE LABS PLC / FESCHMANN HOLDINGS LTD

CARLLO PLC RESIGNED 31/12/2005.

NOTES

Show the full forenames, NOT INITIALS. If the director or secretary is a corporation or Scottish firm, show the name on surname line and registered or principal office on the usual residential line.

Give previous forenames or surname(s) except:

- for a married woman, the name by which she was known before marriage need not be given.
- for names not used since the age of 18 or for at least 20 years

A peer or individual known by a title may state the title instead of or in addition to the forenames and surname and need not give the name by which that person was known before he or she adopted the title or succeeded to it.

Other directorships.

Give the name of every company incorporated in Great Britain of which the person concerned is a director or has been a director at any time in the past five years.

You may exclude a company which either is, or at all times during the past five years when the person concerned was a director, was

- dormant
- a parent company which wholly owned the company making the return, or
- another wholly owned subsidiary of the same parent company.



Companies House

for the record

Please complete in typescript,
or in bold black capitals.

288a

APPOINTMENT of director or secretary (NOT for resignation (use Form 288b) or change of particulars (use Form 288c))

CHWP000

Company Number

406711

Company Name in full

BESPAK PLC

Date of
appointment

Day Month Year
1 1 0 9 2 0 0 6

†Date of
Birth

Day Month Year
1 3 1 1 1 9 6 8

Appointment form

Appointment as director

☒

as secretary

☐

Please mark the appropriate box. If appointment is
as a director and secretary mark both boxes.

NAME

*Style / Title

MR

*Honours etc

Notes on completion
appear on reverse.

Forename(s)

JONATHAN

Surname

GLENN

Previous
Forename(s)

Previous
Surname(s)

†† Tick this box if the
address shown is a
service address for
the beneficiary of a
Confidentiality Order
granted under the
provisions of section
723B of the
Companies Act 1985

†† Usual residential
address

42 HAZEL ROAD, PARK STREET,

Post town

STALDANS

Postcode

AL2 2AT

County / Region

HERTS

Country

ENGLAND

†Nationality

BRITISH

†Business occupation

†Other directorships
(additional space overleaf)

Consent signature

Date

11.09.2006

* Voluntary details.

† Directors only.

**Delete as appropriate

A director, secretary etc must sign the form below.

Signed

Date

11.09.2006

(*a director / secretary / administrator / administrative receiver / receiver manager / receiver)

You do not have to give any contact
information in the box opposite but if you
do, it will help Companies House to
contact you if there is a query on the
form. The contact information that you
give will be visible to searchers of the
public record..

Miss J M Owen, Bepak plc, Blackhill Drive, Featherstone Road, Wolverto

Mill South, Milton Keynes, MK12 5TS

Tel 01908 525211

DX number

DX exchange

Companies House receipt date barcode

This form has been provided free of charge
by Companies House

When you have completed and signed the form please send it to the
Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ DX 33050 Cardiff
for companies registered in England and Wales or

Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB

for companies registered in Scotland

DX 235 Edinburgh
or LP - 4 Edinburgh 2

Company Number

406711

† Directors only.

† Other directorships

NOTES

Show the full forenames, NOT INITIALS. If the director or secretary is a corporation or Scottish firm, show the name on surname line and registered or principal office on the usual residential line.

Give previous forenames or surname(s) except:

- for a married woman, the name by which she was known before marriage need not be given.
- for names not used since the age of 18 or for at least 20 years

A peer or individual known by a title may state the title instead of or in addition to the forenames and surname and need not give the name by which that person was known before he or she adopted the title or succeeded to it.

Other directorships.

Give the name of every company incorporated in Great Britain of which the person concerned is a director or has been a director at any time in the past five years.

You may exclude a company which either is, or at all times during the past five years when the person concerned was a director, was

- dormant
- a parent company which wholly owned the company making the return, or
- another wholly owned subsidiary of the same parent company.



Companies House
for the record

Please complete in typescript,
or in bold black capitals.

CHWP000

288b

Terminating appointment as director or secretary (NOT for appointment (use Form 288a) or change of particulars (use Form 288c))

Company Number

406711

Company Name in full

BESPAK PLC

Date of termination of appointment

Day	Month	Year
26	07	2006

as director

☒

as secretary

☐

Please mark the appropriate box. If terminating
appointment as a director and secretary mark
both boxes.

NAME

*Style / Title

MR

*Honours etc

Please insert
details as
previously
notified to
Companies House.

Forename(s)

MARTIN PETER

Surname

HOPCROFT

†Date of Birth

Day	Month	Year
17	08	1960

A serving director, secretary etc must sign the form below.

Signed

J. M. Owe

Date

31. 7. 06.

* Voluntary details.

† Directors only.

** Delete as appropriate

You do not have to give any contact
information in the box opposite but
if you do, it will help Companies
House to contact you if there is a
query on the form. The contact
information that you give will be
visible to searchers of the public
record.

(** serving director / secretary / administrator / administrative receiver / receiver manager / receiver)

MR. JENNY OWEN. BESPAK PLC, BLACKHILL DRIVE,
FEATHERSTONE ROAD, WOLVERSON MILLS SOUTH, MILTON
KEYNES, BUCKS MK12 5TS. Tel 01908 525211
DX number DX exchange

Companies House receipt date barcode

This form has been provided free of charge
by Companies House.

When you have completed and signed the form please send it to the
Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ DX 33050 Cardiff
for companies registered in England and Wales or
Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB
for companies registered in Scotland

DX 235 Edinburgh
or LP - 4 Edinburgh